The Expression and Potential Significance of Human Kallikreins 6, 7, 8, 10, 13, and 14 in the Epithelium of Selected Odontogenic Cysts and Tumors of Variably Aggressive Biological Behaviour by Woodford, Rebecca
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
9-8-2014 12:00 AM 
The Expression and Potential Significance of Human Kallikreins 6, 
7, 8, 10, 13, and 14 in the Epithelium of Selected Odontogenic 
Cysts and Tumors of Variably Aggressive Biological Behaviour 
Rebecca Woodford 
The University of Western Ontario 
Supervisor 
Dr. Tom Daley 
The University of Western Ontario Joint Supervisor 
Dr. Mark Darling 
The University of Western Ontario Joint Supervisor 
Dr. Michael Shimizu 
The University of Western Ontario 
Graduate Program in Pathology 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Rebecca Woodford 2014 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Oral Biology and Oral Pathology Commons 
Recommended Citation 
Woodford, Rebecca, "The Expression and Potential Significance of Human Kallikreins 6, 7, 8, 10, 13, and 
14 in the Epithelium of Selected Odontogenic Cysts and Tumors of Variably Aggressive Biological 
Behaviour" (2014). Electronic Thesis and Dissertation Repository. 2422. 
https://ir.lib.uwo.ca/etd/2422 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
  
THE EXPRESSION AND POTENTIAL SIGNIFICANCE OF HUMAN KALLIKREINS 6, 
7, 8, 10, 13, AND 14 IN THE EPITHELIUM OF SELECTED ODONTOGENIC CYSTS 
AND TUMORS OF VARIABLY AGGRESSIVE BIOLOGICAL BEHAVIOUR. 
  
 
by 
 
 
Rebecca Woodford 
 
Department of Pathology 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master 
of Pathology 
 
 
 
 
The School of Graduate and Postdoctoral Studies 
Western University 
London, Ontario, Canada 
 
 
Rebecca Woodford 2014 
 
 
 
  
 
 
ii
ABSTRACT 
 
This study analyzed the immunohistochemical staining, localization and relative 
concentrations of human kallikreins (KLKs) 6,7,8,10,13,14 to determine if there is a 
predilection for odontogenic epithelium and if differential staining could predict biological 
behavior of selected odontogenic lesions.  
 We found that all KLKs studied were present in the epithelium of all lesions 
examined. However, there were significant differences in location of intra-epithelial staining 
and staining scores between the lesions. There was no significant, unexplainable difference 
in staining between odontogenic cysts and the control cyst indicating no specific role in 
odontogenic cystogenesis. However, the odontogenic neoplasms showed statistically 
significant increased expression of KLK13, supported by increases in KLK10, suggesting a 
role in odontogenic neoplasia. Our data indicate that this is a secondary role, not related to 
cell cycling, but likely related to differentiation. We suggest that KLKs 13 and 10 may be 
useful as in-situ markers on tissue sections to screen for aggressiveness of odontogenic 
tumors.  
 
 
 
 
 
 
 
 
KEYWORDS: Odontogenic, Cysts, Odontogenic Tumors, Human Tissue Kallikreins, Tumor 
Biomarkers. 
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Chapter 1 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Tooth Development 
1.1.1 Tooth Function 
Teeth are important in everyday functions, such as mastication, providing a 
stable occlusion, as well as providing an esthetic and appropriate facial height and 
balance.  However, cysts and tumors may develop from the tissues that form teeth. 
1.1.2 Tooth Crown Development 
The first sign of tooth development in humans, histologically, occurs in the 
6th to 7th weeks of embryogenesis when thickening of the stomatodeal epithelium of 
the first branchial arch occurs in the areas where tooth formation will take 
place.(Nanci, 2003) Ectomesenchyme and epithelial interactions are necessary for tooth 
formation.(Nanci, 2003) If odontogenic ectomesenchyme is combined with any 
epithelium, the epithelium induces tooth forming gene expression in the 
mesenchyme and tooth structures develop.(Nanci, 2003)  However, if odontogenic 
epithelium is added to any mesenchyme, the epithelium loses its dental 
characteristics and assumes the epithelial characteristics of the origin of the 
mesenchyme.(Nanci, 2003) 
Tooth development occurs in 3 continuous stages: 1. Bud stage, 2. Cap stage, 
and 3. Bell stage.  During the bud stage, the first epithelial infiltration into the 
ectomesenchyme of the jaw occurs forming the dental lamina, with bud-like 
enlargements where the teeth will develop.  The epithelial cells show little to no 
  
 
 
2 
change in their shape or function.(Nanci, 2003)  The supporting ectomesenchymal cells 
then congregate below and about the epithelial bud.(Nanci, 2003)  The epithelial bud 
continues to proliferate around the ectomesenchyme, forming a cap-like structure 
(cap stage), bringing along with it a portion of the dental lamina.(Nanci, 2003) At this 
point it is possible to differentiate the formative elements of the tooth and its 
supporting tissues.(Nanci, 2003) The cap of epithelium, designated the enamel organ, 
will eventually form the enamel of the tooth.(Nanci, 2003)  The ball of ectomesenchyme, 
designated the dental papilla, will form the pulp and dentin of the tooth.(Nanci, 2003)  
The surrounding tissues of the condensed ball of ectomesenchyme, designated the 
dental follicle, will form the periodontal ligament and alveolar bone.(Nanci, 2003)  The 
combination of the enamel organ, the dental papilla, and the dental follicle, form 
what is called the dental organ or tooth germ.(Nanci, 2003)  Lastly, the bell stage occurs 
as the crown of the tooth assumes its final shape.(Nanci, 2003) Ameloblasts and 
odontoblasts, which are cells that eventually produce the hard tissues of the crown, 
undergo histodifferentiation.(Nanci, 2003)  Outer enamel epithelium surrounds the 
boundaries of the enamel organ, and inner enamel epithelium is composed of the 
cells of the enamel organ that lie adjacent to the dental papilla.(Nanci, 2003)  The outer 
and inner epithelia meet at a point, which is named the cervical loop.  Cells here 
continue to divide until the tooth’s crown form has reached its complete size.(Nanci, 
2003)  Once the crown form has been completed, the cells of the cervical loop will 
continue to divide to form Hertwig’s root sheath which migrates apically and 
induces the formation of the tooth root.(Nanci, 2003)   In the crown a layer of cells, 
which are found between the inner enamel epithelium and stellate reticulum, 
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differentiates to form the stratum intermedium, which produces large amounts of 
alkaline phosphatase.(Nanci, 2003)  
The dental lamina breaks up into residual islands of epithelium, providing a 
separation of the developing tooth from the oral epithelium.(Nanci, 2003) These islands 
of epithelium usually involute but some may persist as dental lamina cell rests, 
which have been thought to give rise to some odontogenic cysts and tumors.(Nanci, 
2003)  The inner enamel epithelium produces enamel matrix and odontoblasts form 
pre-dentin.(Nanci, 2003)   
1.1.3 Amelogenesis 
Enamel formation, also known as amelogenesis, has three phases:                     
1. secretory, 2. transition, and 3. maturation.(Simmer & Hu, 2002)  The secretory phase 
occurs with the secretion of enamel matrix proteins as well as proteases by 
ameloblasts.(Simmer & Hu, 2002)   Uncleaved enamel proteins are found on the 
surface/outer enamel layer, whereas cleaved products are found in the 
deeper/inner enamel layer.(Simmer & Hu, 2002)  Proteins such as amelogenin, 
ameloblastin and enamelin are the significant proteins involved in the laying down 
of enamel crystals.(Simmer & Hu, 2002)  Once these proteins are secreted, they are cleaved 
by enzymes and are degraded or reabsorbed by ameloblasts.(Simmer & Hu, 2002)  This 
secretory phase involves growth of the crystals in length, causing expansion of the 
enamel layer.(Simmer & Hu, 2002)  The crystallite lengthening occurs at a mineralization 
barrier which is close in proximity to the secretory surfaces of ameloblasts.(Simmer & 
Hu, 2002)  Mineral is deposited on the apices and sides of the crystallite.(Simmer & Hu, 2002)  
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The transition phase involves ameloblast reorganization of intracellular 
components, once crystallites have attained their final length.(Kallenbach, 1974)  
Approximately one quarter of ameloblasts undergo apoptosis.(Simmer & Hu, 2002)  It has 
been shown in rats that ameloblasts begin to express KLK4 at this point in 
time.(Simmer & Hu, 2002)  KLK4 acts to destroy the proteins in enamel that sustain cell 
adhesion to the mineral layer.(Simmer & Hu, 2002)   
 With the removal of enamel proteins, the maturation phase occurs with 
mineral being deposited only on the sides of the crystallites, causing widening and 
thickening of the crystallites, until contact with adjacent crystallites occurs, 
impeding growth.(Simmer & Hu, 2002)  This allows hardening of the enamel layer.(Simmer & 
Hu, 2002) The final enamel is comprised of approximately 85% mineral crystals.(Smith, 
1998)  
 
1.2 Odontogenic Cysts and Tumors 
1.2.1 Odontogenic Cysts 
As a group, odontogenic cysts are quite common, whereas odontogenic 
tumors are relatively uncommon.(Neville, Damm, Allen, & Bouquot, 2002)  Most of these lesions 
are found within the jaw bones, but some may occasionally be found in the gingiva 
or alveolar mucosa.(Neville et al., 2002) Odontogenic cysts can be classified as either 
developmental or inflammatory.   It is currently unknown why or how 
developmental odontogenic cysts occur.(Neville et al., 2002)   
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Some examples of developmental odontogenic cysts are: lateral periodontal 
cyst, dentigerous cyst, orthokeratinized odontogenic cyst, and glandular 
odontogenic cyst.  
  
1.2.1.1 Lateral Periodontal Cyst 
1.2.1.1.1 Clinical Features 
Lateral periodontal cysts are typically found between the roots of adjacent 
vital teeth on routine radiographs, especially in the maxilla between the lateral 
incisor and cuspid teeth and in the mandible between the bicuspid teeth.(Neville et al., 
2002)  They tend to present in the 5th-7th decade and are very rare in individuals less 
than 30 years of age.(Neville et al., 2002)   
1.2.1.1.2 Histopathologic Features 
The lateral periodontal cyst consists of a non-inflamed, thin, fibrous wall, and 
a thin non-keratinized epithelial lining of flat squamous epithelial cells, or cuboidal 
cells, one to four layers thick.(Neville et al., 2002)  Glycogen-rich cells with clear cytoplasm 
may be present sometimes in clusters called “plaques”.(Fonseca, Turvey, & Marciani, 2009; Neville 
et al., 2002)   
1.2.1.1.3 Treatment and Prognosis 
The typical treatment of lateral periodontal cysts is conservative 
enucleation.(Neville et al., 2002)  Recurrence is very rare. (Fonseca et al., 2009; Neville et al., 2002) 
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1.2.1.2 Dentigerous Cyst 
Dentigerous cysts envelop the crowns of impacted or unerupted teeth and 
are the most common developmental odontogenic cyst.(Neville et al., 2002)   
1.2.1.2.1 Clinical Features 
Dentigerous cysts may be associated with any unerupted tooth, but most 
commonly occur around the crowns of mandibular third molars.(Fonseca et al., 2009; Neville 
et al., 2002)  These cysts can present in patients of all ages, but most develop in patients 
between the ages of 10-30 yrs old. (Neville et al., 2002) Dentigerous cysts have a slight 
male predilection, and present more commonly in white than in black 
populations.(Neville et al., 2002)   
Dentigerous cysts may increase in size and present as large lesions 
associated with asymptomatic expansion of bone and cause displacement of the 
associated tooth.(Fonseca et al., 2009; Neville et al., 2002) A large dentigerous cyst may cause 
displacement of a mandibular third molar superiorly into the mandibular ramus or 
inferiorly to the inferior border of the mandible.(Neville et al., 2002)  A large cyst may also 
cause displacement of maxillary anterior teeth into the nose or of maxillary 
posterior teeth into the maxillary sinus.(Neville et al., 2002) 
On images, the cyst appears as a well defined, unilocular radiolucency which 
surrounds the crown of an impacted/unerupted tooth.(Neville et al., 2002)   
1.2.1.2.2  Histopathologic Features 
The typical non-inflamed dentigerous cyst presents with a loose fibrous 
connective tissue wall with variable amounts of glycosaminoglycans and 
odontogenic epithelial rests, which may present as islands or strands.(Fonseca et al., 2009; 
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Neville et al., 2002) Non-keratinized stratified squamous epithelium of variable thickness 
with cuboidal basal cells and a flat connective tissue interface comprises the 
epithelial lining of the cyst.(Fonseca et al., 2009; Neville et al., 2002)  
1.2.1.2.3  Treatment and Prognosis 
 
The typical treatment of a dentigerous cyst involves the enucleation of the 
cyst as well as extraction of the associated impacted/unerupted tooth.(Fonseca et al., 2009; 
Neville et al., 2002)  
For large dentigerous cysts, marsupialization may be performed in order to 
allow the cyst to shrink and minimize the surgical bony defect after eventual 
surgical currettage. (Neville et al., 2002)  Dentigerous cysts have a good prognosis and have 
a low recurrence rate after complete excision.   
 
 
1.2.1.3 Keratocystic Odontogenic Tumor (KOT) (previously known as the 
Odontogenic Keratocyst (OKC)) 
1.2.1.3.1  Etiology 
 Although it is now considered a neoplasm, it will be described in the section 
of odontogenic cysts since much of the literature regarding KOTs was written when 
it was considered a cyst.  
The KOT exhibits intrinsic proliferation of the epithelial lining.(Neville et al., 2002) 
Further, some sporadic KOTs and those associated with the nevoid basal cell 
carcinoma (Gorlin-Goltz) syndrome have been shown to have mutations in the PTCH 
tumor suppressor gene, and overexpression of bcl-1 and TP53, due to allelic loss, at 
two or more loci, of 9q22.(Barnes , Eveson, Reichart, & Sidransky, 2005) The World Health 
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Organization (WHO) defines the KOT as a “benign uni- or multicystic, intraosseous 
tumor of odontogenic origin, with a characteristic lining of parakeratinized 
stratified squamous epithelium and potential for aggressive, infiltrative 
behavior.”(Barnes  et al., 2005)  
1.2.1.3.2 Clinical Features 
KOTs occur over a wide age range but 60% present in individuals between 
the ages of 10 and 40 years old, and with a slight male predilection.(Barnes  et al., 2005; 
Neville et al., 2002) Roughly 60-80% occur in the mandible, with most presenting in the 
posterior body and ramus of the mandible.(Barnes  et al., 2005; Neville et al., 2002)  Larger KOTs 
may be locally destructive and symptomatic, presenting with pain, swelling, and/or 
drainage.(Barnes  et al., 2005; Neville et al., 2002)  KOTs usually expand in an anteroposterior 
direction within the medullary region of bone and rarely expand the cortical surface 
of the jaw.(Neville et al., 2002)  This allows differentiation from dentigerous cysts and 
radicular cysts as these lesions, when large, will cause bony expansion.(Neville et al., 2002)   
The nevoid basal cell carcinoma (Gorlin-Goltz) syndrome is associated with multiple 
KOTs of the jaws.(Neville et al., 2002) On clinical exam, the cyst lumen is described as 
containing a diagnostic “cream of wheat” fluid, or a cheesy material (keratinaceous 
debris).(Neville et al., 2002)   
1.2.1.3.3 Radiographic Features 
KOTs may present as well defined unilocular or multilocular lesions and may 
have a scalloped border.(Barnes  et al., 2005; Neville et al., 2002)  Approximately 25-40% of cases 
are associated with an unerupted/impacted tooth, They are thought to arise from 
dental lamina rests surrounding the tooth.(Neville et al., 2002)   
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1.2.1.3.4 Histopathological Features 
The histopathological features of KOT’s are diagnostic.  The wall of a KOT is 
lined by a 6-8 cell layer thick stratified squamous epithelium, often devoid of 
inflammatory cells.(Barnes  et al., 2005; Neville et al., 2002)  The boundary between the 
epithelium and connective tissue is flat.(Neville et al., 2002)  The epithelial surface consists 
of parakeratin that is uniform and wavy/corrugated.(Barnes  et al., 2005; Neville et al., 2002)  
Desquamation of the parakeratin is often seen.(Barnes  et al., 2005) KOTs contain a 
palisaded layer of cuboidal to columnar basal epithelial cells that have 
hyperchromatic nuclei, which may be displaced away from the basement 
membrane.(Barnes  et al., 2005; Neville et al., 2002)   In 7-26% of KOTs the fibrous wall may 
contain small islands or strings of odontogenic epithelium.(Neville et al., 2002)   
1.2.1.3.5 Treatment and Prognosis 
The typical treatment of a KOT involves enucleation and curettage of the 
lesion.(Neville et al., 2002)  Overall, larger studies have shown a recurrence rate of roughly 
30%.(Neville et al., 2002) Typically, the majority of recurring KOTs will do so within the 
first 5 years after surgical removal, yet they may recur for up to 10 years.(Neville et al., 
2002)   
Despite the high rate of recurrence, KOTs have a good prognosis.(Neville et al., 
2002)  Rarely, a KOT may expand significantly, invade the base of the skull, or become 
aggressive.(Neville et al., 2002)  
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1.2.2 Odontogenic Tumors 
Odontogenic tumors are a large group of lesions with different clinical and 
prognostic features.(Neville et al., 2002)  Odontogenic tumors range in aggressiveness 
from hamartomas to malignant neoplasms.(Neville et al., 2002) Included in this group are 
tumors of odontogenic epithelium, odontogenic ectomesenchyme, and both 
odontogenic epithelium and ectomesenchyme simultaneously (mixed odontogenic 
tumors which may contain dental hard tissues).(Barnes  et al., 2005; Neville et al., 2002)  Details 
of these tumors can be found in widely used publications.(Barnes  et al., 2005; Neville et al., 2002)  
The ameloblastoma and the odontoma are studied in this thesis.    
 
1.2.2.1 Ameloblastoma 
1.2.2.1.1 Etiology  
Of all of the epithelial odontogenic tumors, ameloblastomas are considered to 
be the most significant and most common.(Neville et al., 2002)  Although ameloblastomas 
are classified as benign neoplams, they are locally invasive.(Neville et al., 2002)  The 
dysregulation of multiple genes required for tooth formation may be involved in the 
formation of ameloblastomas.(Barnes  et al., 2005) There are three different clinical types 
of ameloblastomas that have differing frequencies, clinical and radiographic 
features, and different treatment regimens and prognosis.   In this thesis, only the 
conventional/solid/multicystic intra-bony type was studied.  
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1.2.2.1.1.1 Conventional, Solid or Multicystic Ameloblastoma 
1.2.2.1.1.1.1 Clinical Features  
This type of ameloblastoma can occur in any age, but rarely occurs in those 
under 20 years of age.(Barnes  et al., 2005; Neville et al., 2002) There is a predilection for the 3rd 
to 7th decades of life.(Barnes  et al., 2005; Neville et al., 2002)  They occur in equal frequency in 
males and females with a slight tendency to occur more often in black patients.(Neville 
et al., 2002)  They most commonly (80-85%) occur in the molar region or ascending 
ramus of the mandible, with only 15% occurring in the maxilla, usually 
posteriorly.(Barnes  et al., 2005; Neville et al., 2002)  They may present as a painless swelling of 
the jaw.(Neville et al., 2002)  Ameloblastomas have the potential to grow to a large size and 
cause facial deformity.(Neville et al., 2002) 
1.2.2.1.1.1.2 Radiographic Features 
On radiographic examination ameloblastomas may have a “soap-bubble” 
appearance, composed of large loculations, or a “honeycomb” pattern, composed of 
smaller loculations, in an overall multilocular radiolucent tumor.(Neville et al., 2002)  
These lesions may expand the jaw bone and frequently cause root resorption of 
nearby teeth. (Barnes  et al., 2005; Neville et al., 2002) Ameloblastomas have been found around 
impacted third molars, and can mimic a cyst when they appear unilocular.(Barnes  et al., 
2005; Neville et al., 2002)   
1.2.2.1.1.1.3 Histopathologic Features 
This type of ameloblastoma may contain both cystic and solid areas.(Neville et al., 
2002) There are different microscopic variants classified according to their 
histopathologic features. These are: 1. Follicular, 2. Plexiform, 3. Acanthomatous, 4. 
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Granular Cell, 5. Desmoplastic, and 6. Basal Cell.(Neville et al., 2002)  There is no significant 
difference in prognosis for the different types. 
The classical follicular subtype is the easiest to diagnose and is also the most 
common pattern seen.(Neville et al., 2002)  It occurs in a mature fibrous stroma as 
epithelial islands, which have loose angular cells resembling stellate reticulum in the 
center and are surrounded by a basal layer of palisaded cuboidal to columnar 
ameloblast-like cells that exhibit nuclear hyperchromasia and reversed 
polarity.(Barnes  et al., 2005; Neville et al., 2002)  
The plexiform subtype does not have islands of epithelium, but rather 
narrow, interconnected strands or ropes of epithelium consisting of ameloblast-like 
basal cells enclosing loose epithelial stellate reticulum-like cells.(Neville et al., 2002)  A 
loose, vascular stroma surrounds the epithelium.(Neville et al., 2002)   
1.2.2.1.1.1.4 Treatment and Prognosis 
Treatment options vary from simple enucleation and curettage to en bloc 
resection of the jaw.(Neville et al., 2002)  Because ameloblastomas are aggressive, they 
infiltrate through marrow spaces beyond clinical/surgical or radiographic 
margins.(Barnes  et al., 2005; Neville et al., 2002) Therefore, curettage does not provide complete 
removal of the tumor and is associated with high recurrence rates of 50-90%.(Neville et 
al., 2002)  Marginal resection, with 1cm margins beyond the radiographic boundaries, 
is the usual treatment and has an associated 15% recurrence rate.(Neville et al., 2002) 
Long-term follow-up is important as these lesions may recur even more than 5-10 
years later.(Barnes  et al., 2005; Neville et al., 2002)  Ameloblastomas are rarely fatal (usually 
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from direct extension into the cranium from maxillary lesions) and rarely undergo 
malignant transformation.(Neville et al., 2002)  
 
1.3 Controls 
1.3.1 Odontoma  (Non-neoplastic odontogenic control) 
1.3.1.1 Etiology 
Odontomas are hamartomas of odontogenic tissues.(Barnes  et al., 2005; Neville et al., 
2002) Odontomas contain all of the tissues of a normal tooth (enamel, dentin, 
cementum, and pulp tissue), but do not form proper tooth morphology or size.(Neville 
et al., 2002)  Proliferating odontogenic epithelium and mesenchyme are present in the 
early stages, which lead to the production of dental hard tissues.(Neville et al., 2002)  
There are two types of odontomas: the compound odontoma, which is a focal 
collection of toothlets, and the complex odontoma, which is an irregular gnarled 
mass of dental hard and soft tissues.(Neville et al., 2002) Complex odontomas are less 
common than compound odontomas.(Neville et al., 2002)   
1.3.1.2 Clinical Features 
Odontomas commonly present during the first two decades of life, with a 
mean age of occurrence of 14 years.(Barnes  et al., 2005; Neville et al., 2002)    They are often 
discovered when a radiograph is taken to determine why a tooth has failed to erupt 
into the oral cavity.(Barnes  et al., 2005; Neville et al., 2002)  Odontomas may vary in size, and 
large ones may cause expansion of the jaw bone.(Neville et al., 2002)  They may present in 
either jaw, but are more frequently diagnosed in the maxilla.(Neville et al., 2002)  The 
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compound odontoma has a predilection for the anterior maxilla, and the complex 
odontoma has a predilection for the posterior maxilla or mandible.(Barnes  et al., 2005; 
Neville et al., 2002)   Gender predilection is not present.(Barnes  et al., 2005)   
1.3.1.3 Radiographic Features 
A compound odontoma is a collection of structures that resemble small, 
misshapen teeth surrounded by a radiolucent rim.(Neville et al., 2002)  A complex 
odontoma is also surrounded by a radiolucent rim, but contains a radiopaque mass 
that does not resemble tooth structure.(Neville et al., 2002)   
1.3.1.4 Histopathologic Features 
The compound odontoma is composed of tooth-like structures that are 
present in a loose fibrous stroma.(Neville et al., 2002)  Enamel matrix, dentin, and pulp 
tissue, are found on microscopic examination, even if mature enamel areas are lost 
during slide decalcification.(Neville et al., 2002)  Tissues similar to tooth germs in normal 
teeth are seen in early lesions.(Neville et al., 2002)  The complex odontoma demonstrates 
mature tubular dentin which encloses spaces where mature enamel was present 
prior to decalcification (enamel matrix may be seen here).(Barnes  et al., 2005; Neville et al., 
2002)  Follicular fibrous tissue is also observed surrounding the odontoma. 
1.3.1.5 Treatment and Prognosis 
Odontomas are treated by curettage or local excision.(Barnes  et al., 2005; Neville et al., 
2002)  Odontomas are associated with an excellent prognosis, and recurrence is 
extremely rare.(Neville et al., 2002)  Not all odontomas require removal. 
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1.3.2 Nasopalatine Duct Cyst (Non-Odontogenic Control Cyst) 
1.3.2.1 Etiology 
The nasopalatine duct cyst is the most common non-odontogenic cyst of the 
oral and maxillofacial region, with an incidence of 1%.(Fonseca et al., 2009; Neville et al., 2002)  It 
is believed to arise from the embryonic nasopalatine duct.  In this study, 
nasopalatine duct cysts were used as a control.   
1.3.2.2 Clinical Features 
Nasopalatine duct cysts can present at any age, but are usually observed in 
the 4th-6th decades of life, and are more common in males.(Fonseca et al., 2009; Neville et al., 
2002)  The common symptoms that a patient presents with are swelling of the 
anterior palate, drainage, pain, and long duration of symptoms as they tend to be 
intermittent.(Neville et al., 2002)  On the other hand, many may be asymptomatic and are 
found incidentally on routine radiographs.(Fonseca et al., 2009; Neville et al., 2002)  
1.3.2.3 Radiographic Features 
On radiographic examination, the nasopalatine duct cyst appears as a well-
circumscribed radiolucency between the roots of the maxillary central incisors 
(midline of the anterior hard palate).(Fonseca et al., 2009; Neville et al., 2002)  It often appears as 
a heart-shaped radiolucency because of radiographic superimposition of the 
anterior nasal spine.(Fonseca et al., 2009; Neville et al., 2002)   
1.3.2.4 Histopathologic Features 
Nasopalatine duct cysts may be lined by non-keratinized stratified squamous 
epithelium (most common), pseudostratified columnar epithelium, simple columnar 
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epithelium (+/- cilia and goblet cells), simple cuboidal epithelium, or any 
combination of these epithelial types.(Fonseca et al., 2009; Neville et al., 2002)  
1.3.2.5 Treatment and Prognosis 
The typical treatment of nasopalatine duct cysts is surgical enucleation.(Neville 
et al., 2002)  Recurrence is very rare.(Fonseca et al., 2009)  
 
1.4 Human Kallikreins (KLKs) 
1.4.1 History of Kallikreins 
The year 2009 marked the 100th year since kallikrein research began.(Lawrence, 
Lai, & Clements, 2010)   Werle and colleagues first described a high protein isolate in the 
pancreas in the 1930’s, which they named “kallikrein,” after the Greek word for 
pancreas, but this protein had been previously noted in urine by Abelous and 
Bardier.(Borgono & Diamandis, 2004; Borgono, Michael, & Diamandis, 2004; Lawrence et al., 2010; Lundwall et al., 2006; 
Yousef & Diamandis, 2001) KLK1 was the first kallikrein described, and was originally found 
to release vasoactive kinin peptides from kininogens, resulting in 
hypotension.(Lawrence et al., 2010) As knowledge of the structure and purpose of the 
kallikrein-related peptidase locus increased, the understanding of kallikreins 
advanced.(Lawrence et al., 2010)  KLK1 was recognized to be a part of a multigene 
family.(Lawrence et al., 2010)  Subsequently, KLK2 and KLK3 were described.(Lawrence et al., 
2010)  By the 1990’s the human kallikrein family expanded as more serine peptidase 
encoding genes were discovered and linked to the kallikrein locus.(Lawrence et al., 2010)  
Eventually, the family expanded to 15 kallikreins, with KLK1, KLK2, and KLK3 being 
regarded as the classical kallikreins.(Lawrence et al., 2010)  KLK2 and KLK3 have a greater 
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amino acid similarity with KLK1 than do the remaining KLKs.(Harvey et al., 2000; Lawrence et 
al., 2010)  The kallirein proteins are written in standard font (ex: KLK3) while the 
corresponding gene is written in italics (ex: KLK3).(Lundwall et al., 2006)  
 
1.4.2 Human Kallikrein Locus Organization 
The human kallikrein locus is present at chromosome 19q13.3-13.4 and is 
the longest consecutive arrangement of peptidases found in humans, approximately 
265 kb in length.(Lawrence et al., 2010)   The distance between individual genes ranges 
from approximately 1.5 kb between KLK1 and KLK15 to 32.5 kb between KLK4 and 
KLK5.(Lawrence et al., 2010)  This arrangement, however, may be disrupted in tumor cells, 
including copy number gains of the locus in ovarian, breast, and bladder cancer cell 
lines.(Bayani et al., 2008; Lawrence et al., 2010) The human kallikrein locus organization is 
complex and is not entirely understood at this point. 
 
1.4.3 Structure of Human Kallikrein Genes 
Not only are human kallikrein genes located on the same chromosome, but 
they are also similar in function and form.(Lawrence et al., 2010)  All KLKs consist of five 
coding exons, with exon 1 encompassing the 5’UTR and start codon, and exon 5 
encompassing the termination codon and 3’UTR.(Lawrence et al., 2010) Exons 2,3, and 5 
contain the catalytic triad of histidine, aspartate, and serine residues.(Lawrence et al., 2010)  
All of the genes have the same intron phases and splice sequences, except for a 
variation in KLK10.(L. Luo et al., 1998; Yousef & Diamandis, 2001)  The noncoding portions of the 
human kallikrein genes, however, vary greatly.(Lawrence et al., 2010) 
  
 
 
18
1.4.4 Kallikrein Protein Structures 
Kallikreins must become proteolytically active through cleavage as they are 
produced as preproenzymes.(Lawrence et al., 2010)  As kallikreins are produced, they must 
go to the endoplasmic reticulum via an amino acid signal peptide and be 
secreted.(Lawrence et al., 2010)  Once they are secreted, the signal peptide is cleaved off 
and the kallikrein is now active.(Lawrence et al., 2010)  This allows for a change in the 
binding site of the kallikrein, allowing the kallikrein to bind and cleave various 
substrates.(Hedstrom, 2002)    The cleavage is brought about by peptidases, including 
other kallikreins, that are similar to trypsin, as they cleave the signal peptide at 
residues such as arginine16 or lysine16.(Yoon et al., 2009; Yoon et al., 2008; Yoon et al., 2007)  The 
exception is KLK4, which is cleaved by a matrix metallopeptidase or a cysteine 
peptidase and has a glutamine16 residue.(Lawrence et al., 2010; Simmer & Hu, 2002; Tye, Pham, Simmer, 
& Bartlett, 2009)   Those kallikreins with an arginine16 residue, KLKs 1,2,3,5,9, and 11, are 
more easily activated by other kallikreins than those with a lysine16 residue.(Yoon et al., 
2009; Yoon et al., 2007) Some kallikreins can activate themselves, such as KLKs 2,5,11,12, 
and 14.(Brattsand, Stefansson, Lundh, Haasum, & Egelrud, 2005; Memari, Jiang, Diamandis, & Luo, 2007; Michael et al., 
2005; Mikolajczyk et al., 1997; Vaisanen et al., 1999; Yoon et al., 2007) Regarding the thrombostasis axis, 
several involved peptidases also cleave specific kallikreins.(Yoon et al., 2008)   
The catalytic triad of hisitidine, aspartate, and serine is what makes human 
kallikreins active.(Lawrence et al., 2010)  Serine is responsible for initiating the proteolytic 
activity of kallikreins by targeting a carboxyl group within a substrate.(Hedstrom, 2002)  
The substrate binding region of kallikreins at residue 189 is what determines which 
specific substrates a particular kallikrein will bind.(Lawrence et al., 2010)  The kallikreins 
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have different residues at site 189, with KLKs 1,2,4,5,6 and 10-14 having an 
aspartate residue, KLK3 having a serine residue, KLK7 having an asparagine residue, 
KLK 9 having a glycine residue, and KLK15 having a glutamate residue at this 
site.(Lawrence et al., 2010) Also, around the opening of the active site of the kallikrein there 
are eight loops of residues and exosites on the protein’s surface, that further define 
the substrate specificity of each kallikrein.(Debela et al., 2008)   
In roughly 50% of the human kallikreins, almost 50% of the amino acid 
residues are preserved.(Clements, Willemsen, Myers, & Dong, 2004)  The kallikreins contain the 
same 39 amino acids, of which 37 are also present in trypsin.(Lawrence et al., 2010)  The 
particular amino acids that are important for proteolysis and folding of the proteins 
are similar between kallikreins, whereas the amino acids that determine specificity 
for substrates vary between kallikreins.(Lawrence et al., 2010)  The residues that are 
identical between kallikreins are 10 disulfide bridge-forming cysteine residues, as 
well as those residues in the catalytic triad.(Lawrence et al., 2010) Also, Glycine193 is found 
in all human kallikreins, with the exception of KLK10, which has a glutamate residue 
at this site.(Lawrence et al., 2010)  This variation of KLK10 may be the reason for KLK10’s 
absence of proteolysis of the usual kallkrein substrates.(Zhang et al., 2006)  The region 
where the most diversity exists between kallikreins is the eight loops of the active 
site.(Lawrence et al., 2010)  Although these external loops vary between kallikreins, the core 
structure is identical, thus indicating that various kallikreins can use the same 
mechanism to cleave different substrates.(Lawrence et al., 2010) 
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1.4.5 Proteolytic Functions of Kallikreins 
Kallikreins can be created and be active in a local region, or they can be 
secreted into bodily fluids.(Lawrence et al., 2010)  Kallikreins have various functions and 
they fall into various groups, such as: extracellular matrix proteins, growth factors, 
cell adhesion proteins, signaling molecules, and cell surface receptors.(Lawrence et al., 
2010)  Kallikrein 1 (KLK1) cleaves kininogen, a low molecular weight substrate, at 
two sites, creating kallidin (lys-bradykinin), which can be further cleaved by other 
peptidases to produce des-Arg -kallidin.(Moreau et al., 2005)  These two end-products then 
bind to bradykinin receptors 1 and 2, carrying out the functions of KLK1.(Lawrence et al., 
2010)  This then leads to the creation of nitric oxide, prostaglandins, as well as other 
mediators that ultimately lead to smooth muscle contraction and relaxation, 
inflammation, vasodilation, and pain.(Bhoola, Figueroa, & Worthy, 1992; Moreau et al., 2005)  This 
creates a protective function in medical conditions such as ischemic stroke, renal 
disease, and cardiovascular disease.(Chao, Bledsoe, Yin, & Chao, 2006)  On the other hand, it 
worsens inflammatory conditions, such as asthma.(Chao et al., 2006)    
Kallikreins 2,5,8, and 14 cleave low and high molecular weight kininogen.  
KLK2 also generates kinin, but much less efficiently than KLK1.(Borgono, Michael, Shaw, et al., 
2007; Deperthes et al., 1997; Michael et al., 2005; Rajapakse et al., 2006; Rajapakse & Takahashi, 2007)  Other 
kallikreins function by activating and/or inactivating other kallikreins; KLKs 2,5,12, 
and 14 activate other kallikreins while KLK5 and KLK14 first activate then 
inactivate KLK3.(Emami & Diamandis, 2008; Michael et al., 2006; Yoon et al., 2009; Yoon et al., 2008)  Kallikreins 
also take part in enzyme cascades as KLK1 can activate matrix metallopeptidases 2 
and 9, and KLKs 2,4, and 8 can activate urokinase-type plasminogen activator, thus 
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amplifying or altering the reaction to a particular stimulus.(Beaufort et al., 2006; Rajapakse, 
Ogiwara, Takano, Moriyama, & Takahashi, 2005; Takayama, Fujikawa, & Davie, 1997; Takayama, McMullen, Nelson, 
Matsumura, & Fujikawa, 2001; Tschesche, Michaelis, Kohnert, Fedrowitz, & Oberhoff, 1989)   
Kallikreins have been shown to have a role in skin desquamation as KLK1 
and KLKs 4-14 are all evident in skin tissue.(Brattsand & Egelrud, 1999; Hansson et al., 1994; Komatsu et 
al., 2005; Komatsu et al., 2003; Lundwall & Brattsand, 2008; Pampalakis & Sotiropoulou, 2007; Stefansson, Brattsand, Ny, Glas, 
& Egelrud, 2006)  They cause skin deqaumation by breaking down various desmosomal 
adhesion proteins found in the outer layer of skin.(Borgono, Michael, Komatsu, et al., 2007; Caubet et 
al., 2004)  Activation of cathelicidins, which are antimicrobial, may be brought about by 
KLK5 and KLK7, aiding innate immunity in the skin.(Yamasaki et al., 2006)  When KLK7 is 
overexpressed in the skin of mouse models, inflammation and itching occurs, and 
when KLK8 is knocked out, there is prolonged recovery of ultraviolet B-irradiated 
skin.(Hansson et al., 2002; Kirihara et al., 2003)  Thus, kallikreins may be possible targets for 
therapy to treat skin disases.(Lawrence et al., 2010)   
Kallikreins also have a role in reproduction via cleavage of semenogelins I 
and II, which are the main gel-forming proteins in semen.(Jonsson, Lundwall, & Malm, 2006; 
Lawrence et al., 2010) Kallikreins 2,3, and 11 are the most common kallikreins found in 
semen, although all KLKs are present in semen.(Emami et al., 2009; Shaw & Diamandis, 2007)   
Kallikreins 2,3,5, and 14 cause fluidity of semen by cleaving semenogelins, thus 
allowing sperm to move.(de Lamirande, 2007; Deperthes et al., 1996; Emami, Deperthes, Malm, & Diamandis, 
2008; Lilja, 1985; Michael et al., 2006)  KLK8 is involved in semen liquefaction.(Pampalakis & 
Sotiropoulou, 2007)  Other kallikreins may cleave semenogelins, fibronectin, or other 
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seminal components, or may take part in enzyme pathways.(Takayama et al., 2001; Veveris-
Lowe, Kruger, Walsh, Gardiner, & Clements, 2007)   
 
1.4.6 Kallikrein Expression in Specific Tissues 
Kallikrein expression has been observed in many different body tissues, and 
overlap has been noted.(Gan et al., 2000; Harvey et al., 2000; Lawrence et al., 2010; Shaw & Diamandis, 2007; Su et 
al., 2004)  For example, the prostate contains high concentrations of KLK2 and 
KLK3.(Stanbrough et al., 2006)  KLK1 has been observed in high levels in the pancreas, 
kidney, and salivary glands. (Lawrence et al., 2010) KLK6 is found in high levels in the 
central nervous system.(Lawrence et al., 2010) KLK8 has been found in high levels in 
tissues from the esophagus, skin, and fetal tissues of ureter and tonsil and in lower 
levels in tissues from testis, fallopian tubes, breasts, tonsils, salivary glands, and 
lymph nodes.(Darling, Tsai, Jackson-Boeters, Daley, & Diamandis, 2008; Kishi, Grass, Soosaipillai, Shimizu-Okabe, & 
Diamandis, 2003)  KLK8 has also been shown to be highly expressed in various fluids, 
such as, breast milk, amniotic fluid, seminal fluid, follicular fluid, cerebrospinal fluid 
(CSF), and serum.(Darling et al., 2008; Kishi et al., 2003)  Despite higher concentrations in 
specific tissues, no kallikrein is entirely specific to a particular tissue.(Lawrence et al., 2010)  
Salivary glands contain almost all of the kallikrein family.(Diamandis, Yousef, Luo, Magklara, & 
Obiezu, 2000; James, Pudek, Berean, Diamandis, & Archibald, 1996; Petraki, Karavana, & Diamandis, 2003; Shaw & Diamandis, 
2007; Yousef & Diamandis, 2001)    The lowest level kallikreins in the body are KLK14 and 
KLK15.(MacDonald, Southard-Smith, & Kroon, 1996; Penschow, Drinkwater, Haralambidis, & Coghlan, 1991; Shaw & 
Diamandis, 2007)  
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Genes adjacent to one another on the gene locus often have alike 
expression.(Lawrence et al., 2010)  As an example, KLK2, 3 and 4 are adjacent to one 
another in the locus, and their proteins are all present in prostate tissue.(Lawrence et al., 
2010)  As well, KLK5, 6, 7, and 8 are adjacent genes and their proteins are found in 
ovarian cancer.(Yousef, Polymeris, et al., 2003)  Kallikreins 2,3,4,14, and 15, are expressed in 
the luminal epithelial cells in the prostate, which supports the fact that they are also 
found in seminal plasma.(Veveris-Lowe et al., 2007)  Further, glandular epithelial cells in 
visceral organs express KLK2,3,5,7,8,10,13,14 and 15.(Berglund et al., 2008; Petraki, Papanastasiou, 
Karavana, & Diamandis, 2006)   
KLK4 has a role in tooth mineralization and KLK8 has a role in skin 
desquamation.(Lawrence et al., 2010)   
 
1.4.7 Role of Kallikreins as Biomarkers 
Kallikreins may have a role as biomarkers due to their conserved expression 
profile in particular tissues.(Paliouras, Borgono, & Diamandis, 2007)  KLK3, also known as 
prostate-specific antigen (PSA), is the most researched and most understood of the 
kallikrein family.  PSA has been used as a tissue and serum biomarker for prostate 
cancer for many years.(Kuriyama et al., 1980; Lilja, Ulmert, & Vickers, 2008; Pinzani et al., 2008; Stamey et al., 
1987) However, KLK3 is also found in increased levels in benign prostatic hyperplasia 
(BPH).(Kuriyama et al., 1980; Stamey et al., 1987)  There have been studies done to find other 
kallikreins, such as KLK2, to aid PSA (KLK3) as a biomarker.(Kwiatkowski et al., 1998)    
Kallikreins have not only been researched as biomarkers for prostate cancer, but 
also for conditions of the breast, ovaries, lung, skin, and the nervous system.(Lawrence 
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et al., 2010) KLK8 has been shown to be increased in ovarian cancer, and has been 
proposed as a novel biomarker for ovarian cancer, as well as an independent and 
favourable prognostic marker for ovarian cancer.(Darling et al., 2008; Kishi et al., 2003; Magklara et 
al., 2001; Yousef, Polymeris, et al., 2003)    KLK8 has been found to inhibit cell invasion and 
motility in non-small cell lung carcinoma.(Sher et al., 2006) KLK8 has also been shown to 
be overexpressed in cervical carcinoma, and has been thought to be a potential 
diagnostic tool for determining therapy response, to detect early recurrence post-
therapy, and to function as a target antigen for treatment in those cervical 
carcinomas that are resistant to standard therapy.(Cane et al., 2004; Darling et al., 2008)  As well, 
KLK8 overexpression may be a potential biomarker for the diagnosis of endometrial 
cancer.(Jin et al., 2006)  Hashem et al. showed that KLK14 may serve as a biomarker of 
salivary gland tumors.(N. N. Hashem et al., 2010) KLK13 has also been shown to be increased 
in several salivary gland tumors.(Darling, Jackson-Boeters, Daley, & Diamandis, 2006b)   
Studies have shown that it is beneficial to measure multiple kallikreins in a disease 
as biomarkers as the combination of kallikreins has greater specificity than 
individual kallikrein expression.(Lawrence et al., 2010) Therefore, it is important to have an 
understanding of the variable kallikrein expression in specific diseases, as well as, 
more importantly, the combination of kallikrein expression in conditions in order to 
fully understand their significant potential as biomarkers. 
 
1.4.8 Kallikreins in Odontogenesis and Amelogenesis 
 KLK4 is initially secreted during the transition phase and plays a role during 
the maturation phase of amelogenesis, during which the final enamel crystal 
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formation occurs.(Simmer & Hu, 2002)  In the maturation phase, KLK4 allows crystallites 
to achieve their ideal dimensions and greatest mineralization by removing 
extracellular matrix proteins in the developing enamel.(Simmer & Hu, 2002; Wright et al., 2006)  
KLK4 is the principal enzyme involved in removal of enamel matrix proteins, 
including amelogenin, and destruction of junctions between ameloblasts.(Clements et al., 
2004; Hu et al., 2002) KLK4 has been designated “enamel matrix serine proteinase 1 
(EMSP1)”.(Clements et al., 2004)  MMP-20 (matrix metalloproteinase 20) is an enzyme that 
is considered the predominant processing enzyme during the secretory phase of 
amelogenesis, while KLK4 is the predominant enzyme that degrades enamel matrix 
proteins, and allows the enamel layer to harden, in the later phases.(Hu et al., 2002)  
Studies have been done in mice, pigs, and humans.(Clements et al., 2004; Hu et al., 2002; Hu et al., 
2000; Wright et al., 2006)  
When KLK4 is mutated, crystalline growth of the enamel is inhibited during 
the maturation stage of tooth/enamel development and protein retention occurs 
resulting in some forms of amelogenesis imperfecta.(Wright et al., 2006) However, the 
thickness of the enamel, as well as the orientation of crystallites and prism 
architecture (which is developed by ameloblasts), are not affected.(Wright et al., 2006)  
KLK4 mutation results in a yellow-brown discoloration of the enamel in affected 
individuals, as seen in patients with the hypomaturation pigmented type of 
amelogenesis imperfecta.(Wright et al., 2006)  Studies have also shown that KLK4 may 
have a role in junctional epithelium and periodontal maintenance after tooth 
eruption.(Clements et al., 2004; Hu et al., 2002; Hu et al., 2000)  Also of note, KLK4 has been shown to 
be expressed by odontoblasts, and therefore may also play a role in cleavage of 
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dentin proteins.(Hu et al., 2002) The role of other KLKs or a KLK cascade in enamel 
mineralization has not been previously investigated. 
 
1.4.9 Kallikrein Role in Cancer, Invasion, and Metastasis 
Studies show that kallikreins play an important role in various cancers.(Borgono 
& Diamandis, 2004)  For example, kallikreins may have roles in different stages of 
metastasis, including KLK3 activation of the TGF-β complex, which is involved in 
activation of epithelial-mesenchymal transformation (EMT).(Derynck, Akhurst, & Balmain, 
2001; Killian, Corral, Kawinski, & Constantine, 1993)  As well, KLKs are involved in the destruction of 
various extracellular matrix proteins, including proteoglycans, collagens, laminins, 
and fibronectin.(Borgono & Diamandis, 2004; Borgono et al., 2004; Emami & Diamandis, 2007a, 2007b)  For 
example, KLK8 exhibits trypsin-like characteristics and can break down casein, 
collagen type IV, fibronectin, high-molecular weight kininogen, and gelatin.(Darling et al., 
2008; Rajapakse et al., 2005)  Another important factor in the destruction of extracellular 
matrix is plasmin, which is released via the uPA-uPAR (urokinase plasminogen 
activator- urokinase plasminogen activator receptor) signaling pathway and the 
induction of matrix metalloproteinases (MMPs), which can be activated by 
KLKs.(Borgono & Diamandis, 2004; Emami & Diamandis, 2007b; Giusti et al., 2005; Sidenius & Blasi, 2003) This 
destruction of extracellular matrix proteins allows the cancer cells to pierce barriers 
and thus invade and metastasize.(Borgono & Diamandis, 2004; Emami & Diamandis, 2007a, 2007b) 
Tumor cell invasion is enhanced in vitro with KLKs 1,3-10, and 13.(Shinoda et al., 
2007)  Also, KLK6 increases E-cadherin shedding and promotes cell proliferation, 
migration, and invasion.(Klucky et al., 2007)   
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Kallikreins may also cause proliferation of tumor cells.   Insulin-like growth 
factor binding proteins (IGFBPs) are cleaved by kallikreins 2-5,11, and 14.(Borgono, 
Michael, Shaw, et al., 2007; Cohen et al., 1992; Koistinen et al., 2002; Matsumura et al., 2005; Michael et al., 2006; Plymate et 
al., 1996; Rajapakse & Takahashi, 2007; Rehault et al., 2001; Sano et al., 2007)  These kallikreins, therefore, 
may increase unbound IGF-I as its affinity for cleaved IGFBPs is decreased, resulting 
in mitogenesis and antiapoptosis.(Fielder et al., 1994)  Specific cell lines may be increased 
in vitro by KLKs 3, 4, and 6.(Klokk et al., 2007; Klucky et al., 2007; Niu et al., 2008; Pampalakis et al., 2009; 
Veveris-Lowe et al., 2005)   
The functions of the different kallikreins vary even within the same 
tumor.(Lawrence et al., 2010)  Kallikreins cannot be deemed tumor activators or 
suppressors because, depending on the tumor type, the particular kallikrein, such as 
KLK6 and KLK10, can either enhance or suppress the tumor’s progression.(Klucky et al., 
2007; Lawrence et al., 2010; Pampalakis et al., 2009; Ruckert et al., 2008; Zhang et al., 2006)  Overall, KLK 
overexpression in malignant tumors has, paradoxically, been shown to be associated 
with both favourable and poor prognosis.(Borgono & Diamandis, 2004; Darling et al., 2008; N. N. Hashem 
et al., 2010) 
 
1.4.10 Summary of Known Functions and Locations of KLKs Used in this Study 
1.4.10.1  KLK6:  
 
Functions: 
o involved in tumor invasion, E-cadherin shedding, and promotion of 
cell proliferation and migration,(Klucky et al., 2007; Lawrence et al., 2010)  in 
various cancers including those of the breast, salivary glands, prostate 
and colon.(Darling et al., 2006b; N.N. Hashem et al., 2011; Lin et al., 2002; L. Y. Luo, Grass, & 
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Diamandis, 2000; Palmer et al., 2003; Pampalakis & Sotiropoulou, 2006; Shaw & Diamandis, 2008; Ting, 
Bao, Reeder, Messing, & Lee, 2007; Yousef, Chang, & Diamandis, 2000; Yousef & Diamandis, 2000; Yousef, 
Luo, Scherer, Sotiropoulou, & Diamandis, 1999; Yousef, Magklara, & Diamandis, 2000; Yousef, Scorilas, & 
Diamandis, 2000; Yousef et al., 2002)
 
o has a role in multiple sclerosis and immune mediated demyelination 
diseases in the central nervous system (CNS), in Alzheimer’s disease 
and in Parkinson’s disease(Clements et al., 2004) 
o has also been implicated as a tumor suppressor in breast cancer(Klucky 
et al., 2007; Lawrence et al., 2010; Pampalakis et al., 2009; Ruckert et al., 2008; Zhang et al., 2006)
 
o causes pro-hormone activation of insulin, glucagon, somatostatin, and 
pancreatic polypeptide with KLK1, KLK10, and KLK13(N.N. Hashem, 2008) 
o involved in skin desquamation, myelination and synaptogenesis(N.N. 
Hashem, 2008)
 
Locations: 
o present in all placental mammals.(Lawrence et al., 2010) 
o found in increased levels in the central nervous system,(Lawrence et al., 
2010)  and in several salivary gland tumors,(Darling et al., 2006b; N.N. Hashem et al., 
2011) but appears to be downregulated in comparison with normal 
salivary gland tissue.(Darling, Jackson-Boeters, Daley, & Diamandis, 2006a)   It is 
increased in ovarian cancer,(Yousef, Polymeris, et al., 2003) in some breast 
carcinoma,(L. Y. Luo et al., 2000; Shaw & Diamandis, 2008; Yousef, Chang, et al., 2000; Yousef & 
Diamandis, 2000; Yousef, Fracchioli, et al., 2003; Yousef et al., 1999; Yousef, Magklara, et al., 2000; Yousef, 
Scorilas, & Diamandis, 2000; Yousef et al., 2002) in cervico-vaginal secretion during 
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the  secretory phase of the menstrual cycle,(Shaw, Petraki, Watson, Bocking, & 
Diamandis, 2008)  in cancers of the head and neck, colon, and prostate, as 
well as in normal and altered skin keratinocytes in humans in 
response to vitamin D3,(Lin et al., 2002; Palmer et al., 2003; Ting et al., 2007)  and in 
semen.(Emami et al., 2009; Shaw & Diamandis, 2007) 
o found in decreased amounts in prostate cancer,(Lawrence et al., 2010)  and in 
VK2 vaginal epithelial cells in response to estrogen.(Shaw et al., 2008)   
o observed predominantly in the islets of Langerhans in the normal 
endocrine pancreas, foci of nesidioblastosis and insulin-, glucagon-, 
and somatostatin-producing tumors, along with KLKs 10 and 13. 
The precise role in the pancreas is not yet known.(Clements et al., 2004) 
1.4.10.2  KLK7: 
Functions: 
o involved in keratinization, stratum corneum formation, and 
turnover/desquamation of skin through the degradation of the cell 
adhesion glycoproteins corneodesmosin and plakoglobin.(Clements et al., 2004) 
o has a role in salivary gland, ovarian, breast, lung, cervical, and 
endometrial cancers, and is involved in tumor invasion, activation of 
cathelicidins (aiding innate immunity), and antimicrobial 
function.(Berglund et al., 2008; Darling et al., 2006b; N.N. Hashem et al., 2011; Paliouras et al., 2007; 
Petraki et al., 2006; Shaw et al., 2008; Shinoda et al., 2007; Yamasaki et al., 2006; Yousef, Borgono, et al., 
2004; Yousef & Diamandis, 2000; Yousef, Magklara, et al., 2000; Yousef, Polymeris, et al., 2003; Yousef, 
Scorilas, Magklara, Soosaipillai, & Diamandis, 2000)
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Locations: 
o present in all placental mammals.(Lawrence et al., 2010) 
o shown to be increased in several salivary gland tumors,(Darling et al., 2006b; 
N.N. Hashem et al., 2011)in ovarian cancer,(Yousef, Polymeris, et al., 2003) in glandular 
epithelial cells in visceral organs,(Berglund et al., 2008; Petraki et al., 2006)  in 
cervico-vaginal secretion during the secretory phase of the menstrual 
cycle,(Shaw et al., 2008) in breast carcinoma,(Yousef, Borgono, et al., 2004; Yousef & 
Diamandis, 2000; Yousef, Magklara, et al., 2000; Yousef, Scorilas, Magklara, et al., 2000) in skin 
keratinocytes in response to vitamin D,(Lu et al., 2005) and in semen.(Emami 
et al., 2009; Shaw & Diamandis, 2007) 
o present in the cerebrospinal fluid (CSF) of patients with Alzheimer’s 
disease and dementia(Clements et al., 2004) 
1.4.10.3  KLK8: 
Functions:  
o functions as a tumor suppressor gene in breast cancer, along with 
KLKs 6 and 10.(Klucky et al., 2007; Lawrence et al., 2010; Pampalakis et al., 2009; Ruckert et al., 
2008; Zhang et al., 2006) 
o implicated in tumor cell invasion and cancers, such as as salivary 
gland cancer, ovarian cancer, skin cancer, cervical cancer, endometrial 
cancer, breast cancer, and lung cancer(Borgono et al., 2003; Cane et al., 2004; Darling 
et al., 2006b; Darling et al., 2008; N.N. Hashem et al., 2011; Inoue et al., 1998; Jin et al., 2006; Kishi et al., 
2003; Kuwae et al., 2002; L. Y. Luo et al., 2000; Magklara et al., 2001; Paliouras et al., 2007; Paliouras & 
Diamandis, 2007, 2008; Shaw & Diamandis, 2008; Sher et al., 2006; Yousef, Chang, et al., 2000; Yousef & 
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Diamandis, 2000; Yousef, Fracchioli, et al., 2003; Yousef et al., 1999; Yousef, Magklara, et al., 2000; Yousef, 
Polymeris, et al., 2003; Yousef, Scorilas, & Diamandis, 2000; Yousef et al., 2002) (in non-small cell 
lung cancer, KLK8 seems to inhibit cancer cell invasion and 
motility(Sher et al., 2006)) 
o exhibits trypsin-like characteristics and can break down casein, 
collagen type IV, fibronectin, high-molecular weight kininogen, and 
gelatin, thus aiding in the destruction of the extracellular matrix.(Darling 
et al., 2008; Rajapakse et al., 2005)   
o involved in skin desquamation, myelination and synaptogenesis,(N.N. 
Hashem, 2008) cleavage of low and high molecular weight kininogen, 
activation of a urokinase-type plasminogen activator, amplifying or 
altering the reaction to a particular stimulus,(Beaufort et al., 2006; Rajapakse et al., 
2005; Takayama et al., 1997; Takayama et al., 2001; Tschesche et al., 1989)  and involved in 
semen liquefaction.(Pampalakis & Sotiropoulou, 2007) 
o has a role in multiple sclerosis, immune mediated demyelination 
diseases in the CNS, in Alzheimer’s disease and in Parkinson’s 
disease(Clements et al., 2004) 
Locations: 
o present in all placental mammals.(Lawrence et al., 2010) 
o found in increased levels in the esophagus and skin, in fetal tissues of 
ureter and tonsil,(Darling et al., 2008; Kishi et al., 2003) in various fluids, such as, 
breast milk, amniotic fluid, seminal fluid, follicular fluid, cerebrospinal 
fluid (CSF), and serum,(Darling et al., 2008; Kishi et al., 2003) as well as in several 
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salivary gland tumors,(Darling et al., 2006b; N.N. Hashem et al., 2011) in ovarian 
cancer,(Yousef, Polymeris, et al., 2003) in glandular epithelial cells in visceral 
organs,(Berglund et al., 2008; Petraki et al., 2006) in brain tissue,(Chen et al., 1995; Mitsui, 
Tsuruoka, Yamashiro, Nakazato, & Yamaguchi, 1999) in normal and pathological 
skin,(Inoue et al., 1998; Kuwae et al., 2002)in cervical carcinoma,(Cane et al., 2004; Darling 
et al., 2008) in the endometrium and endometrial cancer,(Jin et al., 2006) in 
breast carcinoma,(L. Y. Luo et al., 2000; Shaw & Diamandis, 2008; Yousef, Chang, et al., 2000; 
Yousef & Diamandis, 2000; Yousef, Fracchioli, et al., 2003; Yousef et al., 1999; Yousef, Magklara, et al., 
2000; Yousef, Scorilas, & Diamandis, 2000; Yousef et al., 2002) and in the prostate.(Kishi et al., 
2003; Shaw & Diamandis, 2008; Yousef, Magklara, et al., 2000; Yousef, Scorilas, Jung, Ashworth, & 
Diamandis, 2001)   
o found in decreased levels in tissues from the testis, fallopian tubes, 
breasts, tonsils, salivary glands, and lymph nodes,(Darling et al., 2008; Kishi et 
al., 2003)  as well as in prostate cancer,(Lawrence et al., 2010) and breast 
carcinoma.(Darling et al., 2008; Yousef, Yacoub, et al., 2004)  
1.4.10.4  KLK10: 
Functions: 
o has a role in skin desquamation(Brattsand & Egelrud, 1999; Hansson et al., 1994; 
Komatsu et al., 2005; Komatsu et al., 2003; Lundwall & Brattsand, 2008; Pampalakis & Sotiropoulou, 
2007; Stefansson et al., 2006)   
o is implicated in ovarian cancer, breast cancer, and tumor cell 
invasion(Borgono et al., 2003; Hsieh et al., 1997; L. Y. Luo et al., 2000; L. Y. Luo, Grass, & Diamandis, 
2003; Magklara, Grass, & Diamandis, 2000; Paliouras et al., 2007; Paliouras & Diamandis, 2007, 2008; 
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Shaw & Diamandis, 2008; Shinoda et al., 2007; Yousef, Chang, et al., 2000; Yousef & Diamandis, 2000; 
Yousef, Fracchioli, et al., 2003; Yousef et al., 1999; Yousef, Magklara, et al., 2000; Yousef, Scorilas, & 
Diamandis, 2000; Yousef et al., 2002)  
o KLK6 and KLK10 can either enhance or suppress tumor 
progression.(Klucky et al., 2007; Lawrence et al., 2010; Pampalakis et al., 2009; Ruckert et al., 2008; 
Zhang et al., 2006) KLK10 has been shown to be a tumor suppressor in 
cancers such as breast, prostate, and testicular cancer.(N.N. Hashem, 2008) 
o also involved in pro-hormone activation of insulin, glucagon, 
somatostatin, and pancreatic polypeptide(N.N. Hashem, 2008) 
Locations: 
o present in all placental mammals.(Lawrence et al., 2010) 
o found in increased levels in glandular epithelial cells in visceral 
organs,(Berglund et al., 2008; Petraki et al., 2006)  in ovarian cancer,(Paliouras et al., 2007)  
in breast carcinoma(L. Y. Luo et al., 2000; Shaw & Diamandis, 2008; Yousef, Chang, et al., 2000; 
Yousef & Diamandis, 2000; Yousef, Fracchioli, et al., 2003; Yousef et al., 1999; Yousef, Magklara, et al., 
2000; Yousef, Scorilas, & Diamandis, 2000; Yousef et al., 2002)  (but also has been long 
known as a tumor suppressor in breast cancer),(Anisowicz, Sotiropoulou, 
Stenman, Mok, & Sager, 1996; Liu, Wazer, Watanabe, & Band, 1996; Pampalakis et al., 2009; Zhang et al., 
2006) and in skin keratinocytes.(Lu et al., 2005)   
o found in decreased levels in prostate cancer,(Lawrence et al., 2010)  and in 
VK2 vaginal epithelial cells in response to estrogen.(Shaw et al., 2008)   
o present in the CSF of patients with Alzheimer’s disease and 
dementia(Clements et al., 2004) 
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o observed predominantly in the islets of Langerhans in the normal 
endocrine pancreas, foci of nesidioblastosis and insulin-, glucagon-, 
and somatostatin-producing tumors, along with KLKs 6 and 13. The 
precise role in the pancreas is not yet known.(Clements et al., 2004) 
1.4.10.5  KLK13: 
Functions:  
o has a role in skin desquamation(Brattsand & Egelrud, 1999; Hansson et al., 1994; 
Komatsu et al., 2005; Komatsu et al., 2003; Lundwall & Brattsand, 2008; Pampalakis & Sotiropoulou, 
2007; Stefansson et al., 2006) 
o is involved in salivary gland, ovarian, and breast cancers, and tumor 
cell invasion.(Borgono et al., 2003; Darling et al., 2006b; N.N. Hashem et al., 2011; L. Y. Luo et al., 
2000; Paliouras et al., 2007; Paliouras & Diamandis, 2007, 2008; Shaw & Diamandis, 2008; Shinoda et al., 
2007; Yousef, Chang, et al., 2000; Yousef & Diamandis, 2000; Yousef, Fracchioli, et al., 2003; Yousef et al., 
1999; Yousef, Magklara, et al., 2000; Yousef, Scorilas, & Diamandis, 2000; Yousef et al., 2002) 
o also involved in pro-hormone activation of insulin, glucagon, 
somatostatin, and pancreatic polypeptide. Other KLKs involved are: 
KLK1, KLK6, and KLK10.(N.N. Hashem, 2008) 
Locations: 
o present in all placental mammals.(Lawrence et al., 2010) 
o found in increased levels in several salivary gland tumors,(Darling et al., 
2006b; N.N. Hashem et al., 2011) in  ovarian cancer,(Paliouras et al., 2007) in glandular 
epithelial cells in visceral organs,(Berglund et al., 2008; Petraki et al., 2006)  in 
breast carcinoma,(L. Y. Luo et al., 2000; Shaw & Diamandis, 2008; Yousef, Chang, et al., 2000; 
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Yousef & Diamandis, 2000; Yousef, Fracchioli, et al., 2003; Yousef et al., 1999; Yousef, Magklara, et al., 
2000; Yousef, Scorilas, & Diamandis, 2000; Yousef et al., 2002)  and in skin keratinocytes in 
response to vitamin D.(Lu et al., 2005) 
o observed predominantly in the islets of Langerhans in the normal 
endocrine pancreas, foci of nesidioblastosis and insulin-, glucagon-, 
and somatostatin-producing tumors, along with KLKs 6 and 10. The 
precise role in the pancreas is not yet known.(Clements et al., 2004) 
1.4.10.6  KLK14: 
Functions:  
o plays a role in salivary gland tumors,(Darling et al., 2006b; N.N. Hashem et al., 2011) 
ovarian cancers,(Paliouras et al., 2007)  and breast cancers,(Borgono et al., 2003; L. Y. 
Luo et al., 2000; Paliouras & Diamandis, 2007, 2008; Shaw & Diamandis, 2008; Yousef, Chang, et al., 2000; 
Yousef et al., 1999) as well as tumor invasion,(Briot et al., 2009; Gao, Chao, & Chao, 2010; 
Klucky et al., 2007; Mize, Wang, & Takayama, 2008; Oikonomopoulou, Hansen, Saifeddine, Tea, et al., 
2006; Oikonomopoulou, Hansen, Saifeddine, Vergnolle, et al., 2006; Ramsay, Dong, et al., 2008; Ramsay, 
Reid, et al., 2008; Stephenson, Verity, Ashworth, & Clements, 1999) and skin 
desquamation.(Brattsand & Egelrud, 1999; Hansson et al., 1994; Komatsu et al., 2005; Komatsu et 
al., 2003; Lundwall & Brattsand, 2008; Pampalakis & Sotiropoulou, 2007; Stefansson et al., 2006) 
o also cleaves low and high molecular weight kininogen, and has a role 
in causing fluidity of semen by cleaving semenogelins,(de Lamirande, 2007; 
Deperthes et al., 1996; Emami et al., 2008; Lilja, 1985; Michael et al., 2006) 
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o along with KLKs 2,5, and 12, is known to activate other kallikreins 
while KLK5 and KLK14 first activate, then inactivate, KLK3.(Emami & 
Diamandis, 2008; Michael et al., 2006; Yoon et al., 2009; Yoon et al., 2008) 
o also cleaves insulin-like growth factor binding proteins 
(IGFBPs).(Borgono, Michael, Shaw, et al., 2007; Cohen et al., 1992; Koistinen et al., 2002; Matsumura 
et al., 2005; Michael et al., 2006; Plymate et al., 1996; Rajapakse & Takahashi, 2007; Rehault et al., 2001; 
Sano et al., 2007) 
Locations: 
o present in all placental mammals.(Lawrence et al., 2010) 
o found in increased levels in breast and prostate cancer,(Lawrence et al., 2010; 
Yousef, Bharaj, Yu, Poulopoulos, & Diamandis, 2001) in the luminal epithelial cells in 
the prostate,(Veveris-Lowe et al., 2007) in glandular epithelial cells in visceral 
organs,(Berglund et al., 2008; Petraki et al., 2006) in salivary gland tumors,(N. N. Hashem 
et al., 2010) in ovarian cancer,(Paliouras et al., 2007)  and in breast carcinoma. 
(Borgono et al., 2003; L. Y. Luo et al., 2000; Paliouras & Diamandis, 2007, 2008; Shaw & Diamandis, 2008; 
Yousef, Chang, et al., 2000; Yousef et al., 1999)   
 
 
 
 
1.4.11 Common Known Functions of the KLKs Studied: 
Skin desquamation cascade: involves KLK5, KLK6, KLK7, KLK8, KLK10, KLK13 and 
KLK14.  
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Antimicrobial function: involves KLK7 (Note: KLK5 also involved) 
Semen liquefaction: involves KLK6, KLK7, KLK8, KLK14 (Note: KLK3 also involved) 
Myelination and Synaptogenesis: involves KLK6 and KLK8 
Pro-hormone activation of insulin, glucagon, somatostatin, and pancreatic 
polypeptide: involves KLK1, KLK6, KLK10, KLK13 (Note: KLK1 also involved) 
Carcinogenesis: involves all 15 KLKs 
Amelogenesis: Not previously known in the KLKs we studied, however KLK4 is 
known to be involved.  
 
 
 
 
 
 
 
 
 
 
Chapter 2 
HYPOTHESIS AND RATIONALE 
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2.1 Hypothesis 
In this study, it is hypothesized that the selected odontogenic cysts and 
tumors will show altered expression of the KLKs 6,7,8,10,13, and 14, compared to 
control tissues and that these alterations will be valuable as potential biomarkers 
for the diagnosis of odontogenic cysts and tumors.  In addition, it is hypothesized 
that alterations in kallikrein expression profiles will help differentiate non-
neoplastic odontogenic cysts from low-grade cystic odontogenic neoplasms and an 
aggressive odontogenic neoplasm. We hypothesize that differences will be present 
that will provide insights into cystogenesis and neoplasia of odontogenic epithelium.  
 
2.2 Rationale 
There is a spectrum of clinical behaviour in developmental cysts and 
neoplasms of odontogenic epithelium.  The lateral periodontal cyst has limited 
growth potential and does not recur after enucleation; the dentigerous cyst may be 
aggressive and cause considerable bone destruction; the odontogenic keratocyst is 
now believed to be a cystic neoplasm (the keratocystic odontogenic tumor (KOT)) 
because of its destructive behavior, association with a known mutation of the PTCH 
tumor suppressor gene, and high recurrence rate; and the generic ameloblastoma is 
considered to be an aggressive, locally invasive neoplasm that requires treatment by 
en-bloc or segmental resection. There is little information to help explain this 
behavioural cascade and thus KLKs may help us better understand the molecular 
biology of cystogenesis and neoplasia of odontogenic epithelium.  
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2.3 Aims and Objectives 
1. To determine immunohistochemically if KLKs 6,7,8,10,13, and 14 are 
expressed in the epithelium of lateral periodontal cysts, dentigerous cysts, 
KOTs, ameloblastomas, and in control tissues - nasopalatine duct cysts and 
odontomas. 
2. If staining is present, to determine the epithelial localization of KLKs 
6,7,8,10,13, and 14 in the above listed lesions. 
3. To determine if cystic odontogenic epithelium preferentially expresses any 
or all of the studied KLKs by comparing the studied odontogenic cysts to the 
non-odontogenic nasopalatine duct cyst. 
4. To determine if the KLK expression is different in the odontogenic 
hamartoma (odontoma) compared to the aggressive odontogenic tumor 
(ameloblastoma). 
5. To determine if the differences in the relative expression profiles of these 
KLKs are useful as diagnostic biomarkers among these lesions. 
6. Given objectives 3,4, and 5 above, to determine if KLKs are able to provide 
insights into cystogenesis and neoplasia of odontogenic epithelium. 
 
 
 
Chapter 3 
Materials and Methods 
3.1 Tissue Specimens 
  
 
 
40
Tissue sections and blocks of formalin-fixed, paraffin-embedded cases from 
the archives of the Oral Pathology Diagnostic Service, Western University, London, 
Ontario were obtained. Ten (10) lateral periodontal cysts, 10 dentigerous cysts, 11 
KOTs, 10 ameloblastomas, 10 nasopalatine duct cysts, and 10 odontomas (8 
Complex, 2 Compound), were each stained and analyzed for KLKs 6,7,8,10,13, and 
14. H&E tissues sections were reviewed to confirm the diagnoses, based on the 
criteria published by the WHO (2005).(Barnes  et al., 2005)   
Although our plan was to have 10-11 specimens for each of the odontogenic 
lesions and controls, when tissue sections were cut, some of the specimens lacked 
sufficient tissue for analysis because the blocks were cut through, resulting in less 
than 10 data points for some of the lesions for some of the KLKs.  
 
3.1.1 Criteria for Selection of Odontogenic Tumors, Cysts, and Control Tissues 
Selected odontogenic cysts and tumors were chosen to represent the 
different degrees of aggressiveness of developmental lesions of odontogenic 
epithelium. The odontoma, an odontogenic hamartoma, was chosen as a control 
tissue because it most closely mimics the tissues and cells of a normal developing 
tooth.  Within our frame of reference, ethics approval was not granted to allow us to 
use developing teeth from aborted human fetuses as controls. The nasopalatine duct 
cyst was used as a non-odontogenic cyst of the jaws to assess the influence of 
odontogenic epithelium on KLK expression. The various cells examined in these 
specimens included: basal layer cells, clear cells, preameloblasts, stellate reticulum-
like cells, ghost cells, squamous layer cells, and odontogenic parakeratin.   
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3.2 Assay Methods 
3.2.1 Immunohistochemistry 
In this study, a standard immunoperoxidase staining technique was 
performed to localize the immunohistochemical expression of human tissue KLKs 
6,7,8,10,13, and 14 in the lesions selected.  To ensure the sensitivity of the reactions, 
immunoreactive tissues with known expression of specific KLKs were used as 
positive controls. Table 3.1 lists the positive control tissues for each KLK. Tissue 
sections from the control groups and the odontogenic cysts and tumor groups, 
treated identically, but with the primary antibodies omitted, were used as negative 
controls in the experiments.  Initial pilot experiments had been carried out to 
determine the ideal antibody titre for each KLK.  
 
 
 
 
 
 
 
 
Table 3.1 Positive Controls Used for KLKs 6,7,8,10,13, and 14 
KLK Positive Control 
  
 
 
42
KLK6 Hyperplastic Dental Follicle 
KLK7 Adenoid Cystic Carcinoma 
KLK8 Skin 
KLK10 Salivary Gland 
KLK13 Salivary Gland and Skin  
KLK14 Skin 
 
3.2.2 Antibody Selection 
The primary antibodies that were used in this research study were provided 
by Dr. E.P. Diamandis of the Department of Laboratory Medicine and Pathobiology 
at the University of Toronto, Toronto, Ontario.  All of the antibodies were rabbit 
polyclonal antibodies raised against the kallikreins being investigated (KLKs 
6,7,8,10,13, and 14), and were produced via recombination in a mammalian stable 
cell line system.(Diamandis, Yousef, Soosaipillai, et al., 2000; Petraki et al., 2001)  The KLKs were created 
and purified by high pressure liquid chromatography (HPLC) as previously reported 
by Diamandis et al.(Diamandis, Yousef, Soosaipillai, et al., 2000)  Previous studies, which used 
Western Blotting analysis, have shown these antibodies to be highly specific and to 
lack cross-reactivity with other KLKs.(Diamandis, Yousef, Soosaipillai, et al., 2000; Petraki et al., 2003)   
 
 
 
3.2.3 Paraffin Sections 
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For each formalin-fixed and paraffin-embedded tissue block, 5-µm thick serial 
sections were cut using a microtome (Microm HM 325;GMI Inc., Ramsey, MN) and 
were then transferred to a water bath at 45°C.  Sections were mounted on 
positively-charged microscopic glass slides and dried by incubating in an oven at 
37°C overnight.  Sections had the paraffin removed and were rehydrated by 
immersion in solutions as follows:  
1. Xylene solution immersion for 5 minutes. This is repeated for 5 minutes, then 
3 minutes in 3 different containers. 
2. Absolute alcohol (100% ethanol) immersion for 2 minutes, then for 1 minute 
in a different container. 
3. 95% alcohol immersion for 2 minutes, then for 1 minute in a different 
container. 
4. 70% alcohol immersion for 1 minute. 
5. 100% distilled water immersion for 2 minutes. 
6. Slides were then quenched with fresh 3% hydrogen peroxide in methanol for 
5 minutes. 
7. Slides were then rinsed with distilled water for 5 minutes and then placed in 
phosphate buffered saline (PBS) on a shaker for 5 minutes. 
 
 
 
 
3.2.4 Staining Procedure 
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The staining procedure took place as follows: 
1. Antigen retrieval was performed in citrate buffer (pH 6.0) in a de-cloaking 
chamber and then slides were rinsed in running tap water and in PBS for 5 
minutes. 
2. Slides were blocked in 10% horse serum for 30 minutes at room temperature 
(RT) in a humidified chamber, then the blocking serum was drained onto a paper 
towel.  
3. Slides were then incubated in a humidified chamber with the primary polyclonal 
antibodies (rabbit) for the respective kallikreins investigated at the appropriate 
pre-determined dilution (Table 3.2). Slides which were tested for KLK6 and 
KLK13 were incubated with antibodies for 1 hour at RT whereas those for KLK7, 
KLK8, KLK10, and KLK14 were incubated at 4oC overnight (Table 3.2). 
4. Slides were then rinsed in PBS for 5 minutes on the shaker to remove excess 
antibodies. 
5. Slides were incubated with ImmPRESS kits (ImmPRESS Reagent Kit; Vector 
Laboratories, Burlingame, CA) anti-rabbit horse-radish peroxidase micro-
polymer solution for 30 minutes at RT in a humidified chamber. 
6. Slides were then rinsed in PBS for 5 minutes on the shaker to remove excess 
immunoglobulins. 
7. The enzymatic reaction was developed in a freshly prepared solution of 3,3’-
diaminobenzidine tetrahydrochloride (DAB Substrate Kit for Peroxidase; Vector 
Laboratories, Burlingame, CA) which was prepared while antibodies were being 
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rinsed as follows: to 5 ml dH2O add 2 drops of buffer, 4 drops of DAB, then 2 
drops of H2O2 in that order, with vortexing after each step. 
8. Slides were then incubated with DAB for 10 minutes at RT and were then 
drained into a waste container using distilled water (to stop the reaction). 
9. Slides were then counterstained in Harris Hematoxylin for 1 minute, then rinsed 
in running tap water. 
10. Slides were blued by being immersed 2-3 times in Ammonium Alcohol (2% 
Ammonium Hydroxide in 70% Alcohol) then rinsed in running tap water. 
11. Slides were then dehydrated by immersion in the following reagents in the 
following order:                 
a. 70% Alcohol for 1 minute 
b. 95% Alcohol for 1 minute 
c. 95% Alcohol for 1 minute 
d. Absolute (100%) alcohol for 2 minutes 
e. Absolute alcohol (100%) for 1 minute 
f. Xylene for 5 minutes 
g. Xylene for 3 minutes 
12. Slides were then mounted and cover-slipped in Cytoseal permount (VWR; 
Mississauga, ON). 
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Table 3.2 Antibody Titres and Incubation Times and Conditions for KLKs 
6,7,8,10,13, and 14 
Kallikrein 
Antibody Titre 
(µL antibody/µL of HS) 
Incubation 
KLK6 1/300 1 hour at RT 
KLK7 1/1600 Overnight at 4°C 
KLK8 1/400 Overnight at 4°C 
KLK10 1/400 Overnight at 4°C 
KLK13 1/200 1 hour at RT 
KLK14 1/800 Overnight at 4°C 
 
3.3 Data Collection and Analysis 
3.3.1 Scoring Criteria 
Staining was viewed under light microscopy and assessed in a semi-
quantitative manner by two experienced pathologists (TD, MRD) and a trained 
graduate student (RW) using a previously described method,(Allred et al., 1993; Darling et al., 
2006a; Tuck et al., 1998) which involves assigning a score for intensity of staining (Table 
3.3) and the estimated percentage of cells stained in the specimen (Tables 3.4).  The 
sum of these scores is the Immunoreactive Score (IRS) (also reported as the Overall 
Staining Score (OSS)), (range: 0 for negative staining and 2-8 for positive staining).  
This scoring system is more valid than solely examining the staining intensity as it 
takes into account the percentage of cells stained, therefore giving a more accurate 
assessment of the expression of the KLKs. 
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The average IRS for each of the KLKs in the control groups and study groups 
were compared. All cell types were not present in each tissue examined, but were 
calculated when they were found. The average KLK staining scores were calculated 
for each individual case and then the final IRS was calculated for each KLK in each of 
the different control and study groups.  Although nuclear staining was seen it was 
unclear whether this was caused by cytoplasmic overlap.  Therefore, it was elected 
to assess cytoplasmic and cytoplasmic membrane staining only to ensure accuracy. 
Table 3.3 Scores for Estimated Average of Staining Intensity in Stained Cells 
Score Staining Intensity 
0 None 
1 Weak 
2 Moderate/Intermediate 
3 Strong 
 
Table 3.4 Scores for Estimated Percentage of Cells Stained 
Score Percentage of Cells Stained 
0 0% 
1 <1% 
2 1-10% 
3 10-30% 
4 30-60% 
5 >60% 
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3.3.2 Statistical Analysis 
The IRS of each KLK for each of the odontogenic cysts, tumors and controls 
were analysed and compared.  Means and medians were determined and 
descriptive statistics based on means are reported. Initial tests for significance were 
done using the non-parametric Kruskall-Wallis Test (KW) followed by both the 
Dunn’s Multiple Comparisons Test (Dunn’s) and the Wilcoxon Comparison Test to 
ensure accuracy.  Only results showing statistical significance by both post-tests 
were considered valid.  The level of significance was P<0.05.  The non-parametric 
Spearman’s Rank Correlation Test was performed to determine correlation. 
Analyses were carried out using GraphPad InStat version 3.00 for Windows 95, 
GraphPad Software, San Diego, California, USA and SAS (Statistical Analysis System), 
SAS Institute, Cary, North Carolina, 2014. 
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Chapter 4 
RESULTS 
 
4.1 Patient Demographics 
Clinical parameters including anonymized patients’ gender, age at diagnosis, 
and site of the lesions were obtained (Table 4.1). 
  Mean age and range, expressed in years were:  lateral periodontal cyst: mean 
= 67.9 +/- 9.0, range = 58-84; dentigerous cyst: mean = 42.8 +/- 8.7, range = 26-55; 
KOT: mean = 46.0 +/- 18.2, range = 19-71; ameloblastoma: mean = 52.2 +/- 21.8, 
range = 15-82; nasopalatine duct cyst: mean = 47.7 +/- 26.1, range = 4-81; 
compound odontomas: mean = 14.0 +/-4.2, range = 11-17; complex odontomas = 
16.4 +/- 6.7, range = 7-29; odontomas overall: mean = 15.9 +/- 6.1, range = 7-29. 
This study has been approved by the Review and Ethics Board of Western 
University. (Western University Ethics File #: 6851) 
 
Table 4.1 Clinical Parameters of the Odontogenic and Non-Odontogenic Cysts 
and Tumors 
Lateral Periodontal Cysts 
Age Sex Site 
61 Female Anterior mandible  
84 Female Anterior mandible  
75 Male Left maxilla premolar area. 
79 Female 11/21 area 
69 Male Right mandible 
70 Male Left mandible  
62 Female Left mandible 34 area 
58 Male Right mandible 43/44 area 
59 Female Left mandible  
62 Female Left maxilla 21 area 
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Dentigerous Cysts 
Age Sex Site 
48 Male Impacted 48 
40 Female Impacted 38 
40 Female Impacted 48 
43 Male Impacted 48 
55 Female Impacted 48 
26 Female Impacted 38 
45 Male Impacted 38 
49 Male Impacted 48 
50 Male Impacted 48 
32 Male Impacted 38 
 
Keratocystic Odontogenic Tumors (KOTs) 
Age Sex Site 
34 Male Right mandible 48 area 
32 Female Left posterior mandible. 
71 Male Mandible 33 and 35 area 
19 Female Left ramus 
64 Male Right mandible 46 area 
44 Male Right mandible 
46 Male Mucosa between 27 and 24  
57 Male Left body and ramus 
mandible 
67 Male Maxilla 24 area 
20 Male Left mandible 38 area 
52 Male Left maxilla 24/25 area 
 
Ameloblastomas 
Age Sex Site 
82 Female Lingual to 31 to 42. 
74 Male Left anterior mandible 
35 Female Left posterior mandible  
55 Male Left ascending ramus 
51 Female Left mandible 
15 Female 38 area 
75 Female Right maxillary sinus 
52 Male Right mandible 46 area 
57 Male 32/33 area 
26 Female 35 area 
 
 
  
 
 
51
Nasopalatine Duct Cysts 
Age Sex Site 
81 Male Right maxilla 11 area 
32 Female 11/21 area 
78 Male Incisive canal 
53 Male Anterior maxilla 
12 Male 
Anterior maxilla 
11/21 area 
53 Female Right anterior maxilla 
67 Female Anterior maxilla 
59 Male Right anterior maxilla 
4 Male Hard palate 
38 Female Anterior maxilla 
 
Odontomas 
Complex Odontomas 
Age Sex Site 
29 Female Maxilla 22/23 area 
19 Female Left posterior maxilla 
18 Female Mandible 38 area 
18 Male Maxilla 28 area 
10 Female Maxilla 16 area 
7 Female Right mandible 85 area 
13 Male Left mandible apical to 
73 
17 Female Left maxillary tuberosity 
 
Compound Odontomas 
Age Sex Site 
17 Male Left mandible 32/33 
area 
11 Female Right anterior maxilla 
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4.2 Experimental Results of Staining 
 
The presence and localization of staining for each KLK in each of the studied 
cysts/tumors are illustrated in Figs. 4.1 to 4.6, and crossreferenced in Figs. 4.7 to 
4.12. The mean and median values for the study and control groups versus KLKs are 
presented in Tables 4.2 and 4.3 respectively. Fig 4.13 is a composite of KLK 
immunostaining vs odontogenic cysts, tumors and controls. Figs 4.14 to 4.19 
illustrate the median value of KLK immunostaining and the standard deviation for 
each odontogenic cyst, tumor and control. Figs 4.20 to 4.25 illustrate the median 
value of staining of the odontogenic cysts, tumors and controls for each KLK. Fig 
4.26 illustrates the overall staining score of each KLK per lesions. Fig 4.27 illustrates 
the overall staining score of each lesion per KLK.  Table 4.4 iilustrates the 
statistically significant correlations as determined by the Spearman’s Rank 
Correlation Test. 
Stated magnification in the figures below refers to the power of the objective 
lens when the image was taken. 
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Fig 4.1. Lateral Periodontal Cyst (LPC) immunostaining and localization 
by antibodies to KLKs 6,7,8,10,13,14. 
 
 
LPC – KLK6      LPC – KLK7 
X10 magnification           X10 magnification 
 
 
LPC – KLK8           LPC – KLK10 
X10 magnification            X10 magnification 
 
 
LPC – KLK13     LPC – KLK14 
X10 magnification     X10 magnification 
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Fig 4.2. Dentigerous Cyst immunostaining and localization by antibodies 
to KLKs 6,7,8,10,13,14. 
 
 
Dentigerous Cyst – KLK6          Dentigerous Cyst – KLK7 
X10 magnification           X10 magnification 
 
 
Dentigerous Cyst – KLK8              Dentigerous Cyst – KLK10 
X10 magnification            X10 magnification 
 
 
Dentigerous Cyst – KLK13         Dentigerous Cyst – KLK14 
X10 magnification          X10 magnification 
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Fig 4.3. Keratocystic Odontogenic Tumor (KOT) immunostaining and 
localization by antibodies to KLKs 6,7,8,10,13,14. 
 
KOT – KLK6            KOT – KLK7 
X10 magnification           X10 magnification 
 
 
KOT – KLK8             KOT – KLK10 
X10 magnification            X10 magnification 
 
 
KOT – KLK13            KOT- KLK14 
X10 magnification           X10 magnification 
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Fig 4.4. Ameloblastoma immunostaining and localization by antibodies 
to KLKs 6,7,8,10,13,14. 
 
 
Ameloblastoma – KLK6          Ameloblastoma – KLK7 
X10 magnification           X10 magnification 
 
 
Ameloblastoma – KLK8          Ameloblastoma – KLK10 
X10 magnification           X10 magnification 
 
 
Ameloblastoma – KLK13                       Ameloblastoma – KLK14 
X10 magnification            X10 magnification 
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Fig 4.5. Nasopalatine Duct (NPD) Cyst immunostaining and localization 
by antibodies to KLKs 6,7,8,10,13,14. 
 
 
NPD Cyst – KLK6           NPD Cyst – KLK7 
X20 magnification           X20 magnification 
 
 
NPD Cyst – KLK8           NPD Cyst – KLK10 
X20 magnification           X20 magnification 
 
  
NPD Cyst – KLK13           NPD Cyst – KLK14 
X20 magnification           X20 magnification 
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Fig 4.6. Odontoma immunostaining and localization by antibodies to 
KLKs 6,7,8,10,13,14. 
 
 
Odontoma – KLK6           Odontoma – KLK7 
X10 magnification           X10 magnification 
 
 
Odontoma – KLK8           Odontoma – KLK10 
X10 magnification           X10 magnification 
 
 
Odontoma – KLK13           Odontoma – KLK14 
X10 magnification           X10 magnification 
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Fig 4.7. KLK6 immunostaining of the cysts and tumors studied. 
 
 
        NPD Cyst – X20 magnification               LPC – X10 magnification 
 
 
 
       Dentigerous Cyst – X10 magnification     KOT – X10 magnification 
 
 
 
        Odontoma – X10 magnification    Ameloblastoma – X10 magnification 
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Fig 4.8. KLK7 immunostaining of the cysts and tumors studied. 
 
 
       NPD Cyst – X20 magnification                LPC – X10 magnification 
 
 
 
       Dentigerous Cyst – X10 magnification    KOT – X10 magnification 
 
 
 
        Odontoma – X10 magnification     Ameloblastoma – X10 magnification 
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Fig 4.9. KLK8 immunostaining of the cysts and tumors studied. 
 
 
        NPD Cyst – X20 magnification                LPC – X10 magnification 
 
 
 
      Dentigerous Cyst – X10 magnification     KOT – X10 magnification 
 
 
 
        Odontoma – X10 magnification    Ameloblastoma – X10 magnification 
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Fig 4.10. KLK10 immunostaining of the cysts and tumors studied. 
 
 
        NPD Cyst – X20 magnification               LPC – X10 magnification 
 
 
 
 
      Dentigerous Cyst – X10 magnification     KOT – X10 magnification 
 
 
 
        Odontoma – X10 magnification    Ameloblastoma – X10 magnification 
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Fig 4.11. KLK13 immunostaining of the cysts and tumors studied. 
 
 
        NPD Cyst – X20 magnification               LPC – X10 magnification 
 
 
 
 
       Dentigerous Cyst – X10 magnification    KOT – X10 magnification 
 
 
 
        Odontoma – X10 magnification    Ameloblastoma – X10 magnification 
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Fig 4.12. KLK14 immunostaining of the cysts and tumors studied. 
 
 
        NPD Cyst – X20 magnification                LPC – X10 magnification 
 
 
 
 
       Dentigerous Cyst – X10 magnification    KOT – X10 magnification 
 
 
 
        Odontoma – X10 magnification    Ameloblastoma – X10 magnification 
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Value ± Standard Deviation 
 
 
 
 
 
Table 4.3. Median Values for Odontogenic Cysts/Tumor and Controls vs KLKs 
 Nasopalatine 
Duct Cyst 
Lateral 
Periodontal 
Cyst 
Dentigerous 
Cyst 
KOT Odontoma Ameloblastoma 
KLK6 7.0 7.0 7.0 7.0 7.0 8.0 
KLK7 5.5 7.0 6.0 7.0 6.0 6.0 
KLK8 6.0 7.0 7.0 6.0 6.0 7.0 
KLK10 6.5 7.0 7.0 7.0 7.0 8.0 
KLK13 7.0 6.0 6.0 7.0 6.0 8.0 
KLK14 6.0 7.0 7.0 7.0 5.0 7.0 
 
 
 
 
 
Table 4.2. Mean Values for Odontogenic Cysts/Tumor and Controls vs KLKs 
 Nasopalatine 
Duct Cyst 
Lateral 
Periodontal 
Cyst 
Dentigerous 
Cyst 
KOT Odontoma Ameloblastoma 
KLK6 6.9 ± 1.05 7.3 ± 0.48 6.7 ± 0.46 6.6 ± 
0.50 
7.0 ± 0.00 7.8 ± 0.63 
KLK7 5.6 ± 0.70 6.4 ± 0.97 5.8 ± 0.40 6.6 ± 
0.50 
6.2 ± 0.83 6.1 ± 0.87 
KLK8 6.5 ± 0.71 6.8 ± 0.44 6.7 ± 0.46 6.2 ± 
0.60 
6.3 ± 0.70 6.9 ± 0.31 
KLK10 6.3 ± 1.06 7.0 ± 0.67 6.6 ± 0.69 7.0 ± 
0.00 
6.2 ± 0.97 7.5 ± 0.70 
KLK13 6.7 ± 0.67 6.1 ± 0.33 6.1 ± 0.30 7.0 ± 
0.00 
5.6 
± 2.21 
7.7 ± 0.48 
KLK14 5.7 ± 1.41 6.6 ± 1.24 6.4 ± 0.92 6.6 ± 
0.67 
5.5 ± 0.93 6.7 ± 0.48 
  
 
 
Fig 4.13 Composite of immunostaining mean values vs odontogenic cysts and 
tumors and controls 
 
 
 
Fig 4.14 KLK expression in Nasopalatine Duct Cyst. 
staining score for each KLK in the nasopalatine duct cyst are displayed numerically 
adjacent to each dot plot. 
KLK6 KLK7
6.9 5.6
7.3
6.4
6.7
5.8
6.6
6.6
7.0
6.2
7.8
6.1
Odontogenic Cysts/Tumor and Controls vs 
Nasopalatine Duct Cyst
KOT
Median values of overall 
KLK8 KLK10 KLK13 KLK14
6.5 6.3 6.7
6.8 7 6.1
6.7 6.5 6.1
6.2 7 7
6.3 6.2 5.6
6.9 7.5 7.7
KLKs
Lateral Periodontal Cyst Dentigerous Cyst
Odontoma Ameloblastoma
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5.7
6.6
6.4
6.6
5.5
6.7
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Fig 4.15 KLK expression in Lateral Periodontal Cyst. Median values of overall 
staining score for each KLK in the lateral periodontal cyst are displayed numerically 
adjacent to each dot plot. 
 
 
 
 
 
 
Fig 4.16 KLK expression in Dentigerous Cyst. Median values of overall staining 
score for each KLK in the dentigerous cyst are displayed numerically adjacent to 
each dot plot. 
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Fig 4.17 KLK expression in Keratocystic Odontogenic Tumor. Median values of 
overall staining score for each KLK in the keratocystic odontogenic tumor are 
displayed numerically adjacent to each dot plot. 
 
 
 
 
Fig 4.18 KLK expression in Odontoma. Median values of overall staining score for 
each KLK in the odontoma are displayed numerically adjacent to each dot plot. 
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Fig 4.19 KLK expression in Ameloblastoma. Median values of overall staining 
score for each KLK in the ameloblastoma are displayed numerically adjacent to each 
dot plot. 
 
 
 
 
Fig 4.20  KLK6 expression in odontogenic cysts and tumors and controls. 
Median values of overall staining score for KLK6 in each odontogenic cyst and tumor 
and controls are displayed numerically adjacent to each dot plot. 
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Fig 4.21  KLK7 expression in odontogenic cysts and tumors and controls. 
Median values of overall staining score for KLK7 in each odontogenic cyst and tumor 
and controls are displayed numerically adjacent to each dot plot. 
 
 
 
 
Fig 4.22 KLK8 expression in odontogenic cysts and tumors and controls. 
Median values of overall staining score for KLK8 in each odontogenic cyst and tumor 
and controls are displayed numerically adjacent to each dot plot. 
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Fig 4.23 KLK10 expression in odontogenic cysts and tumors and controls. 
Median values of overall staining score for KLK10 in each odontogenic cyst and 
tumor and controls are displayed numerically adjacent to each dot plot. 
 
 
 
Fig 4.24 KLK13 expression in odontogenic cysts and tumors and controls. 
Median values of overall staining score for KLK13 in each odontogenic cyst and 
tumor and controls are displayed numerically adjacent to each dot plot. 
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Fig 4.25 KLK14 expression in odontogenic cysts and tumors and controls. 
Median values of overall staining score for KLK14 in each odontogenic cyst and 
tumor and controls are displayed numerically adjacent to each dot plot. 
 
 
Fig 4.26. Immunostaining profiles: overall staining score of each KLK per 
lesion (odontogenic cysts and tumors and controls) 
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Fig 4.27. Immunostaining profiles: overall staining score of each lesion 
(odontogenic cysts and tumors and controls) per KLK 
 
 
 
KLK 6 7 8 10 13 14 
6 - KOT All DCyst   
7 KOT - LPC NPD,  
All 
DCyst  
8 All LPC -   NPD, 
DCyst,  
All 
10 DCyst NPD,  
All 
 - All All 
13  DCyst  All - All 
14   NPD, 
DCyst, 
All 
All All - 
Table 4.4  Statistically significant correlations as determined by Spearman’s 
Rank Correlation Test at P<0.05.  “All” indicates the combined data from all 
lesions studied. 
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4.3 Statistical Analysis 
 
Experimental findings indicated that KLK6 was expressed in the epithelium 
of all of the control and study groups but there was variation of median expression 
(KW p=0.0001).  KLK6 was shown to be statistically significantly higher in 
ameloblastomas than in dentigerous cysts, KOTs, and odontomas with post-KW 
comparison tests p<0.001, p<0.001 and p<0.05 respectively for those groups.   
KLK7 was expressed in the epithelium of all tissues, but variation of 
expression was found between the groups (KW p=0.0142). However, post-KW 
comparison tests showed a significant difference in expression only between KOTs 
and nasopalatine duct cysts (p<0.05).   
KLK8 was expressed in the epithelium of all tissues. There was variable 
expression amongst controls, cysts and tumors (KW p=0.0108), with significantly 
higher expression in ameloblastomas than KOTs (post-KW comparison tests 
p<0.05). 
KLK10 was also expressed throughout the epithelium in all tissues studied, 
but was expressed with greatest intensity in the parakeratin layer of KOTs. Variable 
expression of KLK10 was also seen amongst the different groups (KW p=0.0052), 
and expression was found to be significantly higher in ameloblastomas than in 
nasopalatine duct cysts and odontomas (post-KW comparison tests p<0.05 for both 
respectively).  
KLK13 was expressed throughout the epithelium in all tissues studied. There 
was variable expression amongst controls, cysts, and tumors (KW p<0.0001).  When 
comparing expression in ameloblastomas to the other groups using the post-KW 
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comparison tests, a statistically significant greater expression was evident in 
ameloblastomas compared to lateral periodontal cysts (p<0.001), dentigerous cysts 
(p<0.001), and odontomas (p<0.001).   Also, again using the post-KW comparison 
tests, there was a significantly higher expression of KLK13 in KOTs when compared 
to lateral periodontal cysts (p<0.05), dentigerous cysts (p<0.05), and odontomas 
(p<0.05).  
KLK14 was expressed throughout the epithelium in all tissues studied. Unlike 
the other KLKs, KLK14 did not show variable expression between the  
control, cyst, and tumor groups (KW p=0.1202), and no significant difference was 
found between any of the groups studied (post-KW comparison tests p>0.05 for all 
groups).   
 
4.3.1 Summary of Statistical Analysis 
Odontoma   - Variation between all KLKs (Kruskal-Wallis p=0.0168) 
- KLK6 significantly higher than KLK14 (post-KW comparison 
 tests p<0.01) 
 
NPD Cyst  - Variation between all KLKs (KW p =0.0211) 
- KLK6 is significantly higher than KLK7 (post-KW comparison 
tests p<0.05) 
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LP Cyst  -Variation between all KLKs (KW p= 0.0039) 
- KLK6 is significantly higher than KLK13 (post-KW 
comparison tests p<0.01) 
 
Dentigerous Cyst  - Variation between all KLKs (KW p=0.0006) 
- KLK6 is significantly higher than KLK7 (post-KW comparison 
tests p<0.01) 
- KLK8 is significantly higher than KLK7 (post-KW comparison 
tests p<0.01) 
 
KOT    - Variation between all KLKs (KW p = 0.0008) 
- KLK10 is significantly higher than KLK8 (post-KW 
comparison tests p<0.01) 
- KLK13 is significantly higher than KLK8 (post-KW 
comparison tests p<0.01) 
 
Ameloblastoma - Variation between all KLKs (KW p< 0.0001) 
- KLK6 is significantly higher than KLK7 (post-KW comparison 
tests p<0.001) 
- KLK6 is significantly higher than KLK8 (post-KW comparison 
tests p<0.05) 
- KLK6 is significantly higher than KLK14 (post-KW 
comparison tests p<0.01) 
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- KLK10 is significantly higher than KLK7 (post-KW 
comparison tests p<0.01) 
- KLK13 is significantly higher than KLK7 (post-KW 
comparison tests p<0.001) 
- KLK13 is significantly higher than KLK14 (post-KW 
comparison tests p<0.05) 
 
KLK6  - Variation exists amongst controls, cysts and tumors (KW 
 p=0.0001) 
- Significantly higher in Ameloblastoma than Dentigerous Cyst 
(post-KW comparison tests p<0.001) 
- Significantly higher in Ameloblastoma than KOT (post-KW 
comparison tests p<0.001) 
- Significantly higher in Ameloblastoma than Odontoma (post-
KW comparison tests p<0.05) 
 
KLK7   -Variation exists amongst controls, cysts, and tumors (KW 
 p=0.0142) 
- Significantly higher in KOT than NPD cyst (post-KW 
comparison tests p<0.05) 
 
KLK8   - Variation exists amongst controls, cysts and tumors (KW 
    p=0.0108) 
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- Significantly higher in Ameloblastoma than KOT (post-KW 
comparison tests p<0.05) 
 
KLK10   - Variation exists amongst controls, cysts, and tumors (KW 
   p=0.0052) 
- Significantly higher in Ameloblastoma than NPD cyst (post-
KW comparison tests p<0.05) 
- Significantly higher in Ameloblastoma than Odontoma (post-
KW comparison tests p<0.05) 
 
KLK13   - Variation exists amongst controls, cysts, and tumors (KW 
   p<0.0001) 
- Significantly higher in KOT than LP cyst (post-KW 
comparison tests p<0.05) 
- Significantly higher in Ameloblastoma than LP cyst (post-KW 
comparison tests p<0.001) 
- Significantly higher in KOT than Dentigerous cyst (post-KW 
comparison tests p<0.05) 
- Significantly higher in Ameloblastoma than Dentigerous cyst 
(post-KW comparison tests p<0.001) 
- Significantly higher in KOT than Odontoma (post-KW 
comparison tests p<0.05) 
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- Significantly higher in Ameloblastoma than Odontoma (post-
KW comparison tests p<0.001) 
 
KLK14  - NO variation exists amongst controls, cysts, and tumors (KW 
 p= 0.1202) 
- No significant difference found between controls, cysts, and 
tumors (post-KW comparison tests p>0.05) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
4.4 KLK Staining of Specific Tissues
4.4.1 Enamel Matrix 
 Enamel matrix stained with 
same intensity. Staining was most intense with KLK
with KLKs 6, 7 and 10; and minimal (possibly backg
4.28 illustrates KLK staining of enamel matrix in odontomas.
 
 
 
 
 
 
 
 
 
most of the KLKs studied, although not with the 
s 8 and 13; moderately intense 
round staining) with KLK14. 
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4.4.2 Epithelial Layers of Odontogenic Cysts 
 
4.4.2.1 Non-Staining of Basal/Parabasal Layer Cells 
 
 There was a lack of staining of the basal and sometimes the parabasal layer 
cells in NPD cysts by KLKs 6,10; LP cysts by KLKs 6,7 (fig 4.29),10,13, and 14; and 
KOTs by KLKs 6,7,8,10, and 14. 
 
 
 
Fig 4.29: Lack of staining in the basal and parabasal layer cells in an LP cyst with 
KLK7. 
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4.4.2.2 KLK Specific Staining of Parakeratin in KOTs  
 An interesting finding was the diversity of staining of the parakeratin layer of 
KOTs. Heavy staining of parakeratin was found for KLKs 7 and 10 (fig 4.30a), while 
the same layers were unstained or poorly stained by KLKs 8 (fig 4.30b), 13 and 14.  
 
 
 
 
Fig 4.30a: There was heavy staining of the upper layers, especially the parakeratin 
layer by KLK10 in KOTs. 
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Fig 4.30b. KLK8 failed to stain the parakeratin layer (and only weak, inconsistent 
staining of the basal layer) in KOTs. 
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4.4.2.3 Desomsomal Staining 
 Cell membrane staining, interpreted to be desmosomal staining, was found in 
some examples of LP cysts by KLKs 8,10, and 14; dentigerous cysts by KLKs 8,10, 
and 14; odontomas by KLKs 8 and 14; and ameloblastomas by KLKs 7 and 8. (Fig 
4.31) 
 
 
 
Fig 4.31. KLK8 staining of desmosomes of ameloblasts in an odontoma. 
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Chapter 5 
DISCUSSION 
5.1 The Expression of KLKs 6,7,8,10,13, and 14 in Odontogenic Epithelium of 
Cysts and Tumors. 
 This study is the first documentation of the presence of KLKs 6,7,8,10,13 and 
14 in odontogenic epithelium, whether normal or pathological. 
We found that KLK6 was highly expressed in all of the control and study 
groups but variation of expression existed (KW p=0.0001), based largely on the very 
high expression in ameloblastomas.  KLK6 was shown to be statistically significantly 
higher in ameloblastomas than in dentigerous cysts (post-KW correlation tests 
p<0.001), KOTs (post-KW correlation tests p<0.001), and odontomas (post-KW 
correlation tests p<0.05). Since ameloblastomas are the most aggressive tumor, this 
suggests that KLK6 is involved in some way in the behaviour of the more aggressive 
tumors.  
We found that KLK7 expression was generally clustered, and less well 
expressed than the other KLKs with the exception of staining in the KOT. The KOT 
increased staining is likely related to the known function of KLK 7 in keratinization 
and desquamation.(Clements et al., 2004) The expression of KLK7 was significantly higher 
in KOTs than in the control NPD cyst (post-KW correlation tests p<0.05), perhaps 
again related to the known role of KLK7 in keratinization and desquamation, but the 
possibility of specific activity related to odontogenic lesions cannot be dismissed.  
KLKs 6 and 7 showed statistically significant positive correlation (Spearman’s Rank 
Correlation Test p=0.0476) in KOTs. 
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Expression of KLK8 was relatively clustered for all lesions (fig 4.26) with the 
exception of statistically significantly greater expression in ameloblastomas than in 
KOTs (post-KW correlation tests p<0.05), related in part to the lack of staining by 
KLK8 in the basal and keratinized layers of the KOT (fig 4.30b), and the increased 
staining of cell membranes (desmosomes) in the ameloblastoma (fig 4.31). The close 
clustering of staining in all of the lesions, including the NPD Cyst, suggests that KLK8 
is not significantly involved in odontogenic lesions or aggressiveness of these 
lesions.  When all lesions are combined, KLKs 6 and 8 show statistically significant 
correlation by Spearman’s Rank Correlation Test (p=0.0017), confirming the close 
clustering demonstrated in Fig. 4.26. 
KLK10 showed more varied expression (fig 4.26) among the lesions (KW 
p=0.0052) with increased expression in the neoplasms (ameloblastoma, KOT) and 
decreased expression in the controls (NPD Cyst and odontoma) (post-KW 
correlation tests: ameloblastoma vs NPDC: p<0.05; ameloblastoma vs odontoma: 
p<0.05), suggesting a greater role in neoplasia and aggressive behavior.  
Surprisingly, the LP cyst also showed higher levels of KLK10 expression (although 
not statistically significant). The significance of this finding is unknown.  
KLK13 showed the greatest variability in staining intensity among the lesions 
(fig 4.26) (KW p<0.0001, considered highly statistically significant) and continued 
the trend seen with KLK10, of higher expression in the neoplasms and lower in the 
odontogenic cysts (post-KW correlation tests ameloblastoma vs odontoma p<0.001; 
ameloblastoma vs dentigerous cysts p<0.05; ameloblastoma vs LP cyst p<0.001; 
KOT vs LP cyst p<0.05; KOT vs dentigerous cyst p<0.05). This strongly suggests that 
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KLK13 is involved in the process of odontogenic neoplasia. In fact, there was no 
statistical difference between any of the odontogenic cysts and the control NPD Cyst 
indicating that the influence of KLK13 on cyst formation is not specific to 
odontogenic epithelium.  The surprising finding that both KLK10 and KLK13 are 
more highly expressed in odontogenic neoplasms suggest that they may work 
synergistically as part of a KLK cascade. Although, this did not reach statistical 
significance (Spearman’s Rank Correlation Test p=0.1220). 
KLK14 expression was again clustered and lower, and did not show sufficient 
variability to reach statistical significance. (KW p=0.1202) This suggests that KLK14 
is not specifically involved in odontogenic neoplasia or cystogenesis. 
 
5.2 Selected Observations on the Localization of Expression of KLKs 
6,7,8,10,13, and 14  
5.2.1 Reduced or Non-staining of Basal and Parabasal Layer Cells in Cysts. 
 A recurring finding was a partial or complete lack of staining (sparing) of 
basal and parabasal layer cells for some of the KLKs studied.  The LP cyst and KOT 
showed basal sparing for KLKs 6,7,10 and 14, with increased expression in the 
middle epithelial layers (fig 4.29). The dentigerous cyst did not show this 
stratification difference. These observations suggest that KLKs 6,7,10 and 14 are not 
involved in cell cycling (proliferation) but are involved in differentiation, or at least 
maintenance, of specialized epithelium (LP cyst: odontogenic features of rests of 
Serres; KOT: parakeratinization; Dentigerous cysts: simple stratified squamous 
epithelium).  This interpretation is supported by the findings for the control NPD 
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cyst, which also showed basal sparing for KLKs 6 and 7, but increased staining 
intensity in areas showing respiratory epithelium (KLKs 6, 8, and 13). However, the 
fact that both the control and the experimental cysts showed these changes 
indicates that the process is not specific to odontogenic cysts.  
 Klucky et al claimed that KLK6 is involved in cell proliferation, which is 
opposite to our view that KLK6 is not involved in cell cycling.(Klucky et al., 2007)  
However, their study was directed at e-cadherin degradation by KLK6 in cell 
separation and tissue invasion.  
 
5.2.2 Variable Staining of Parakeratin in KOTs and Desmosomal Staining. 
 An interesting finding was the variability of staining between KLKs of the 
parakeratin layer of KOTs. There was consistently increased staining by KLKs 7 and 
10 (fig 4.30a) but, paradoxically, decreased staining by KLKs 8 (fig 4.30b), 13 and 
14. KLKs have been known to be present in skin and involved in the process of 
keratinization (KLK7 – stratum corneum formation),(Clements et al., 2004) and especially 
desquamation (KLKs 5,6,7,8,10,13,14).(Brattsand & Egelrud, 1999; Clements et al., 2004; Hansson et al., 
1994; N.N. Hashem, 2008; Komatsu et al., 2005; Komatsu et al., 2003; Lin et al., 2002; Lu et al., 2005; Lundwall & Brattsand, 
2008; Palmer et al., 2003; Pampalakis & Sotiropoulou, 2006, 2007; Stefansson et al., 2006; Ting et al., 2007)  KLK7 has 
been shown to degrade plakoglobins and corneodesmosin, destroying cell adhesion 
and therefore causing skin desquamation.(Clements et al., 2004; Sondell, Thornell, & Egelrud, 1995; 
Tanimoto et al., 1999)   KLK7 has been shown to be a true marker of terminal differentiation 
in keratinizing, cornifying squamous epithelium.(Clements et al., 2004; Ekholm & Egelrud, 2000)  
KLK8 has also been shown to have role in the terminal differentiation of 
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keratinization.(Clements et al., 2004) The finding of increased KLK7 staining in an 
increasing gradient from parabasal to keratin layer is in agreement with previous 
findings of its involvement in the process of keratinization and desquamation. We 
found KLK10 to follow the same pattern (fig 4.30a). This suggests that KLK10 may 
work in a KLK cascade with KLK7 in the process of desquamation. Desquamation of 
the parakeratin occurs in KOTs.(Barnes  et al., 2005)  Therefore, the increased staining of 
KLKs 7 and 10 in the parakeratin layer of KOTs further desmontrates their role in 
desquamation. Since this is occurring in skin as well as the KOT, the involvement of 
the KLKs seems process driven, rather than tissue specific. The lack or partial lack of 
staining by KLKs 8,13, and 14 is harder to explain, since these KLKs also have been 
shown to cause degradation of adhesion molecules (E cadherin, plakoglobin(Clements et 
al., 2004)and desmoglein 1) in keratin desquamation in skin. One possible answer is 
that skin is orthokeratinized while KOTs are parakeratinized and the desquamation 
process may differ.  In fact, our findings of desmosomal staining by KLKs 8 and/or 
10 in LP cysts, dentigerous cysts, odontomas (fig 4.31), and ameloblastomas 
suggests that these molecules are involved in adhesion in odontogenic epithelium, 
rather than separation of cells. This interpretation would also explain the lack of 
KLKs 8, 13 and 14 in desquamating parakeratin. 
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5.2.3 Staining of Enamel Matrix in the Process of Odontogenesis 
 KLK4 has been studied extensively in the process of odontogenesis.(Clements et 
al., 2004; Hu et al., 2002; Hu et al., 2000; Simmer & Hu, 2002; Wright et al., 2006)  (See Introduction: 1.4.8) 
Enamel matrix, a combination of a number of known proteins including amelogenin 
(about 90% of matrix protein), enamelin, and ameloblastin, is deposited initially to 
form the tooth shape, and is then replaced during calcification in the maturation 
phase, by hydroxyapatite. For calcification to occur, the matrix must be broken 
down and removed. Two proteins are currently known to be involved in this 
degradation: MMP-20 (enamelysin) and KLK4.(Neville, Damm, Allen, & Bouquot, 2009) However, 
it is known that KLKs often work in cascades with other KLKs. In this study using 
enamel matrix produced in the odontomas, we found that KLKs 8 and 13 were found 
in high concentration in enamel matrix, with less intense staining by KLKs 6,7, and 
10. Normal appearing dentin did not stain and negative controls were negative for 
matrix staining. These findings indicate that the ameloblasts likely secrete KLKs 
6,7,8,10 and 13 into the enamel matrix where they may act synergistically with 
KLK4 in enamel matrix degradation during the maturation phase. It is possible that 
other KLKs not yet studied are also involved in this process. Future studies are 
needed to investigate the roles of various KLKs in enamel matrix degradation. 
 
5.3 Semi-quantitative Estimation of KLK Expression 
 The intensity and percentage of staining of each specimen was estimated 
simultaneously by three individuals (see Methods).  This, however, was somewhat 
subjective.  An attempt was made to provide a score for each specimen objectively 
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with a computer program that can analyze specimens for staining intensity and 
percentage of staining of regions outlined by the researcher. However, for technical 
reasons, such as tissue overlap, inability to standardize staining against controls, 
vagueness of background staining, subjectivity in outlining, difficulty in outlining on 
a computer screen, and interpretation of colour variations, the computerized 
program was rendered less reliable than the initial human analysis.  Therefore, after 
comparing results, subjective analysis was interpreted to be more reliable. 
(Axiovision, Carl Zeiss Microimaging GmbH, Goettingen, Germany).   
 
5.4 The Expression of KLKs 6,7,8,10,13, and 14 in Odontogenic Cystic Lesions 
(Lateral Periodontal Cyst, Dentigerous Cyst, KOT) vs the Non-Odontogenic 
Control (Nasopalatine Duct Cyst). 
 All KLKs studied were found in the epithelium of all of the cysts studied, 
including the control, the NPD cyst, indicating a non-specific role for these KLKs in 
cystic epithelial tissues of the jaws. Relative to the control, the NPD cyst, only the 
KOT showed a significant increase in staining with KLK7 (post-KW correlation tests 
p<0.05), which can be adequately explained by the involvement of KLK7 in the 
process of desquamating keratin. The lack of a significant difference in staining of 
the NPD cyst and the odontogenic cysts with any of the other KLKs argues against a 
specific role of these KLKs in odontogenic cystogenesis. However, there were 
significant differences among the odontogenic cysts of different destructive 
potential, at least with respect to KLK13, where the staining in the KOT was found to 
be significantly greater than that seen in both of the other odontogenic cysts, the LP 
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cyst (p<0.05) and the dentigerous cyst (p<0.05). Since KLK13 was found to be under 
expressed in the parakeratin layer of KOTs, the process of keratinization/keratin 
desquamation cannot explain these differences, suggesting that KLK13 may be 
involved in more aggressive behavior and increased potential for recurrence.   
KLK10 appears to have a similar involvement as KLK13 (although not statistically 
significant), and perhaps they work together in a common pathway.  Therefore, 
KLKs 10 and 13 may potentially be useful as biomarkers, if found in human serum, 
for the diagnosis and management of more aggressive odontogenic cystic lesions, 
such as the KOT. 
 
5.5 The Expression of KLKs 6,7,8,10,13, and 14 in the Odontoma (Hamartoma 
Control) vs the Ameloblastoma (Aggressive Odontogenic Neoplasm) 
 To determine if any of these KLKs could impact the process of neoplasia in 
odontogenic epithelium, the staining of the hamartoma – the odontoma – was 
compared to the staining of the most aggressive neoplasm of all benign odontogenic 
tumors – the ameloblastoma. Importantly, the staining intensity of the 
ameloblastoma was significantly more intense than the odontoma for KLK6 (post-
KW comparison tests p<0.05), KLK10 (post-KW comparison tests p<0.05) and KLK 
13 (post-KW comparison tests p<0.001) suggesting a role of these KLKs in more 
aggressive lesions. The upregulation of KLK13 in the KOT, relative to the other jaw 
cysts (see 5.4) supports this interpretation. Exactly how these KLKs are involved in 
aggressive behavior is unknown. It is unlikely that KLKs 6, 10 and 13 are involved in 
increased proliferation (see 5.2.1 basal layer sparing), so the increased expression 
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may simply be related to increased demands on differentiation as a secondary 
response to the increased neoplastic activity.  Hashem et al have previously noted 
that KLK6 and KLK13 seem to be involved in a common pathway in a salivary gland 
tumor (pleomorphic adenoma).(N.N. Hashem, 2008)  Our findings seem to further support 
this relationship between KLK6 and KLK13, and perhaps furthermore involving 
KLK10 in a common pathway or cascade in the development and progression of 
odontogenic neoplasms.  However, this relationship was not shown to be 
statistically significant by Spearman’s Rank Correlation Test. 
Given these findings, KLK13 may be a useful surrogate in situ marker for 
aggressive odontogenic epithelial lesions (KOT, ameloblastoma) similar to p16 for 
HPV detection in some mucosal squamous cell carcinomas.  
Further research is needed to delineate the roles of KLKs 6, 10 and 13 in the 
development and progression of odontogenic neoplasms.  
 
5.6 Diagnostic Markers 
 From our study, it appears that KLKs 6, 10, and 13 are potential candidates to 
be used as diagnostic markers for the more aggressive odontogenic lesions (See 5.4 
and 5.5). Our studies show their usefulness as potential in-situ 
immunohistochemical markers for relative aggressiveness of jaw lesions, but they 
cannot determine odontogenic lineage. For these KLKs to be used as biomarkers for 
the studied odontogenic cysts and tumors, further investigation to determine if 
serum concentrations or salivary concentrations of KLKs, especially KLK13 for 
ameloblastoma, vary with the presence of this tumor, and if serum or salivary 
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concentration of KLK13 could predict recurrence after surgery.  Salivary samples 
would be less invasive than obtaining serum samples for isolating kallikrein 
concentrations. 
 
5.7 Correlations 
 KLK14 did not demonstrate any statistically significant differences using the 
Kruskal-Wallis test. Consequently, it showed the most correlation by Spearman’s 
Rank Correlation Test with KLKs 8,10, and 13, when all lesions are considered 
(p=0.0045, p=0.0096, p=0.0369 respectively). Interestingly, there was a correlation 
of KLKs 8 and 14 for both NPD cyst and dentigerous cyst, again suggesting that KLK 
expression is not specific for odontogenic epithelium. 
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Chapter 6 
CONCLUSIONS 
1) For the first time, KLKs 6,7,8,10,13, and 14 have been documented and 
localized in the epithelium of human odontogenic cysts and tumors. 
2) The localization of various KLKs in odontogenic epithelium and tissues of the 
studied cysts and tumors varied: a) There was sparing of the basal and 
parabasal layers in LP cyst and/or KOT; b) There was increased expression 
in the keratin layer of KOTs by KLKs 7 and 10; c) Cell membrane 
(desmosomal) staining was present in most odontogenic lesions with KLKs 8, 
10, and sometimes 14; d) Enamel matrix in odontomas exhibited staining for 
KLKs 6,7,8,10, and 13.  
3) The role of the studied KLKs in cystogenesis of jaw cysts is not considered to 
be specific for odontogenic epithelium. 
4) KLKs 6,10, and 13 have shown evidence of involvement in the process of 
neoplasia in the ameloblastoma, and KLKs 10 and 13 in the KOT. 
5) KLK10, and especially KLK13, showed greater expression in neoplastic 
tissues relative to cysts and hamartomas, suggesting a potential role as a 
tissue section in-situ marker for odontogenic neoplasia. 
6) Elevated co-expression of KLKs 10 and 13, and possibly KLK6, in 
odontogenic neoplasms suggests that these may act in a KLK cascade. 
Similarly, co-expression of KLKs 6,7,8,10, and 13 in enamel matrix suggests a 
cascade mechanism in conjunction with KLK4 in the resorption of enamel 
matrix during the maturation phase of amelogenesis. 
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